Author: acn

香港, 2026年3月27日 - (亚太商讯 via SeaPRwire.com) - 领先的机电工程与智慧城市的资讯及通讯科技服务供应商安乐工程集团有限公司（「安乐工程」或「公司」，连同附属公司统称「集团」）（股份代号：1977），今天宣布截至2025年12月31日止年度（「年内」或「2025财政年度」）的全年业绩，除净利润录得增长，集团的手头合约更再创新高，订单额增长逾倍，为未来三年及往后的发展奠下稳固基础。财务摘要- 本公司拥有人应占溢利按年增23.5%至1.670亿港元- 手头合约增61.8%至178.787亿港元，再创历史新高，受惠于年内订单额增长113.7%至129.136亿港元- 新增维修保养合约涵盖房屋项目、环保项目以及升降机及自动梯，合约额增51.4%至16.69亿港元，巩固经常性收入来源- 集团维持强健现金水平，银行结余及现金为10.208亿港元，资产负债比率则由26.2%降低至2025财政年度的10.1%- 董事会已决议派付第二次中期股息每股2.9港仙；全年合共派息每股5.5港仙，较上年度増25.6%主席麦建华博士表示：「2025年见证了全球的重大变化，挑战与机遇并存。集团稳步向前，以谨慎履行承诺作坚实基础，不断精益求精，更推动革新落到实处、投资提升技术及生产力，引领香港工程的卓越实力踏上环球市场。我们欣然宣布，集团实现了利润增长，更创下历史新高的手头合约水平，并持续巩固在国际市场的影响力。这些成就彰显了我们在各个业务领域的综合能力，对卓越质量的承诺，以及在先进工程技术方面的领导地位。」「凭着充裕的现金流支持， 我们具实力适时开展更多工程项目，并在高价值商机出现时抓紧机会。我们将继续保持灵活专注，积极把握集团广泛业务组合中的机遇，透过持续提升我们具竞争力的优势，并强化应用创新解决方案，以提升工程质量、安全和表现。我们深知为客户坚定不移地履行承诺，是赢得他们信任及维系持久伙伴关系的基础。秉持『重承诺、慎履行、献成果』的座右铭，我们将继续为客户、股东、供应商和其他持份者创造最高利益，同时为我们所服务的社区作出贡献。」业务回顾：屋宇装备工程- 此业务板块继续成为集团最大的收益来源，收益达32.79亿港元。- 手头合约创下历史新高，达82.97亿港元，于2025财政年度新签合约增长一倍达64.70亿港元。集团在跨多专业的综合项目中拥有竞争优势，并有赖在创新的机电装备合成法和其他新工程技术方面的领导地位成功取得重要合约。- 凭借策略性投资以加快创新，并在珠海和香港发展现代化制造设施，集团得以在机电装备合成法和装配式设计技术方面继续领先同侪。- 集团通过成功取得物业管理牌照扩大业务以提供可横跨整个建筑周期的综合解决方案。此涵盖建造、维修保养、营运，以至长期的设施管理的新能力，开拓了潜在的收益来源，与核心服务互补优势。- 透过不断开发创新技术和优化营运，此业务板块强化自身定位以维持在市场中的竞争优势，同时探索东南亚其他市场的发展机遇。环境工程- 此业务板块的手头合约与新增订单额创下历史新高，分别按年增加86.9%及253.7%至80.94亿港元及53.55亿港元。同时，业务收益按年增加18.0%至15.91亿港元。- 此业务板块于年内维持积极参与投标，并成功赢得标志性合约，包括合约额破纪录的搬迁沙田污水处理厂往岩洞、马鞍山污水泵房等工程项目。- 于庆阳市开立了合营企业，以拓展中国内地的营运及维修业务。- 探索在亚洲和中东地区的项目机遇，并将专业服务拓展至欧洲市场。资讯、通讯及屋宇科技（「ICBT」）- 业务收益维持在6.30亿港元，手头合约价值截至2025年末为8.52亿港元，年内新增订单额为5.23亿港元。- 此业务板块持续以DigiFusion品牌巩固其在绿色及智慧屋宇解决方案的领导地位，有助打造更智慧化、更可持续的城市环境。- 持续凭借安乐工程大厦作为平台以研发创新技术，并透过与中国内地及环球领先生产商的策略合作持续扩大技术能力，从而加强在多个范畴的能力以提供可扩大规模的高效解决方案。升降机及自动梯- 收益与新增订单额分别按年增加11.0%至5.87亿港元，以及增加3.2%至5.66亿港元。- 集团位于美国的联营公司Transel Elevator & Electric Inc（「TEI」）取得重大合约，在耸立于纽约时代广场旁的地标性56层摩天豪华酒店内提供世界级垂直运输系统。TEI亦将业务版图拓展至美国东南部，进一步巩固其市场地位。- 积极加强在英国的业务，并扩大在其他国际市场的网络，强化在垂直运输解决方案领域的全球发展的雄心。- 无机房升降机产品继续在主要国际市场取得进展。- 南京工厂简化了生产流程，扩大产品种类，并提高了整体产品质量。这些提升正好配合集团的环球视野，肯定其承诺，矢志提供可靠和高效的垂直运输解决方案。有关2025年度业绩详情，请参阅已呈交香港联合交易所有限公司的公告。关于安乐工程集团有限公司安乐工程集团有限公司成立于1977年，为领先的机电工程与智慧城市的资讯及通讯科技服务供应商，总部设于香港，业务遍及中国内地、澳门、美国、英国、德国、新加坡及马来西亚。本集团为公共和私营机构提供跨专业综合机电及技术服务，涵盖屋宇装备工程、环境工程、资讯、通讯及屋宇科技（「ICBT」），以及升降机及自动梯等四大业务板块。本集团同时制造及向全球销售升降机及自动梯，并与美国纽约最大独立升降机及自动梯公司之一 – Transel Elevator & Electric Inc.（「TEI」）达成伙伴关系。本集团的联营公司南京佳力图机房环境技术股份有限公司（603912.SS）专门制造精密空调设备。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年3月27日 - (亚太商讯 via SeaPRwire.com) - 3月26日，海天味业（A股：603288；H股：03288）发布2025年年度业绩报告，面对2025年复杂多变的市场环境，凭借多元产品矩阵、高效运营体系、硬核科技创新，公司在行业变革浪潮中稳健前行，交出一份彰显行业龙头实力与高质量发展成色的优异答卷。财报数据显示，2025年公司核心经营指标稳健增长，实现营业收入288.73亿元，同比增长 7.32%。盈利能力同步提升，全年归母净利润70.38亿元，同比增长10.95 %；扣非归母净利润68.45亿元，同比增长12.81%；调味品主业毛利率41.78%，同比增加3.15个百分点；各项经营资料均创下历史新高，盈利质量与增长动力双双亮眼，彰显公司硬核实力。丰富的国民产品矩阵，构筑多元增长格局丰富完善的国民级产品矩阵，是海天味业实现稳健增长的核心基石。在产品矩阵方面，海天围绕用户需求持续推进品类创新，构建起覆盖全场景烹饪的一站式产品体系，全方位满足不同消费群体的多样化需求。得益于丰富的产品矩阵与优异的产品质量，2025年，公司酱油、蚝油、调味酱等核心品类保持稳健发展，分别实现营业收入149.34亿元、48.68亿元及29.17亿元，同比增长8.55%、5.48%及9.29%，构成业务增长的“金字塔基座”。其中，海天酱油产销量和市场占有率已连续数十年位居全国第一，海天蚝油的市场占有率也连续10年位居全国第一，凭借优质口感与稳定质量，成为千万家庭与餐饮机构的首选；公司调味酱已形成产品丰富、风味立体、场景多元的产品体系，涵盖黄豆酱、香辣酱等具备广泛消费基础的大单品，同时亦有柱侯酱、海鲜酱、拌饭酱、香菇酱等适用不同烹饪方式的特色酱料，紫苏酱、桂林风味辣椒酱等适合不同地域口味的风味酱料，以及葱油拌面酱、重庆小面调料等便捷化调味酱，有效满足用户需求。此外，为顺应消费者对醋类产品的细分化需求，公司坚持「传统醋+特色醋」的产品布局，同时不断推陈出新，推出有机醋、果醋等多元化产品，形成丰富多元的醋类产品体系，进一步弥补品类空白，扩大市场覆盖面。截至2025年底，公司拥有7个十亿级以上产品系列、超30个亿级以上产品系列，产品矩阵的丰富度与完整性持续提升。其中，金标生抽、草菇老抽两大产品系列已畅销60余年，味极鲜酱油、海天上等蚝油两大产品系列连续10余年实现单品年收入超10亿元，成为支撑公司业绩稳健增长的「压舱石」，其市场认可度与用户忠诚度持续处于行业领先水平。在保持核心品类稳健增长的同时，海天精准把握消费趋势变化，持续培育新兴增长点，不断丰富产品矩阵的层次与内涵。报告期内，在领先行业的产品力支撑下，以有机和薄盐为代表的营养健康系列产品实现营业收入同比增速达48.3%，成为拉动业绩增长的新引擎；食醋和料酒业务持续发力，规模优势和体系化能力逐步显现，市场占有率稳步提升，为公司长远发展注入强劲新动能。值得关注的是，依托供应链规模效应、技术研发与柔性生产三大核心壁垒，海天加速从“调味产品供货商”向“一站式风味解决方案提供商”转型，深度布局商用市场，实现To C与To B业务双轮驱动。截至2025年底，公司已为众多餐饮连锁、食品工厂及全球头部零售品牌提供商用调味品一站式解决方案，成为公司业绩增长的重要支撑。坚持以用户为中心，全局深耕驱动效率与价值双升坚持以用户为中心，持续优化运营效率与用户价值，是海天味业保持行业领先地位的关键所在。面对消费渠道的多元化变革，海天立足用户需求，通过数字化赋能传统渠道、拥抱新兴渠道建设、联动餐饮及工业渠道，实现效率与价值的双重跃升，进一步巩固市场渗透率。在传统渠道方面，海天依托覆盖全国的终端网络，借助数字化营销工具和服务模式创新，持续向下沉市场渗透，并延伸到最终用家和消费者，显著提高了终端覆盖质量与消费者触达效率，同时，通过终端管理的精细化升级，让存量网点焕发新活力。2025年线下渠道营业收入达257.60亿元，同比增长7.85%。在线与实时零售等新兴阵地，海天主动适应消费场景的变化，通过规范销售秩序、强化专业运营，实现新兴渠道的高质量发展；针对新兴渠道的消费特性，公司还推出线上定制化产品，精准匹配消费群体的需求，逐步构建在线与线下协同互促的健康发展模式，2025年在线渠道增幅高达31.87%。在商用渠道方面，依托柔性供应链与「销研产一体化」快速响应机制，海天为餐饮连锁和食品工厂提供从通用产品到定制化的一站式调味解决方案，实现「3天打样、15天交付」的高效响应，大幅提升了客户体验与合作粘性。目前，餐饮与工业渠道稳健发展，收入占比持续提升，正成长为公司专业增长的重要动力源，进一步拓宽了公司的增长空间。坚持科技立企与创新，驱动价值链全面升级坚持科技立企、创新驱动，是海天味业实现高质量发展的核心动力。作为调味品行业数字化转型的先行者，公司全面拥抱AI时代，推动人工智能、大数据与传统酿造技艺深度融合，在守护匠心工艺的同时实现提质增效，推动行业从「传统酿造」向「智慧酿造」转型升级。海天味业坚持每年将研发投入保持在营业收入约3%的水平，近十年研发投入累计超65亿元，累计拥有各类专利超1,000项，形成了完善的研发体系与创新机制。2025年1月，海天高明生产基地获得全球酱油酿造行业首家「灯塔工厂」认证，标志着公司数字化转型已跻身全球行业标杆，也印证了中国调味品企业在智能制造领域的领先实力。此外，公司部署端到端供应链创新用例，将AI与大数据深度应用于研、产、供、销各环节，实现全链条的数字化、智能化升级。在数字化全面赋能下，海天供应链运营效率显著提升，订单准时足额交付率（OTIF）不断提高，综合成本稳步下降，充分彰显智能制造带来的效率红利与竞争优势。受益于在数字化转型与高质量发展方面的突出成就，海天味业屡获殊荣。2025年，公司斩获「CGF中国供应链数字化与可持续韧性发展案例」「全国制造业数字化转型典型案例」等多项殊荣，得到行业与社会的广泛认可。同时，由海天主导起草的国家标准《食品数字化工厂通用技术要求》正式发布，填补了国内食品行业数字化工厂通用技术标准的空白，为食品行业数智化升级提供「海天范式」，充分彰显了公司的行业带动力与责任担当。回望2025年，海天味业以稳健业绩、多元布局、硬核实力，在高质量发展之路上行稳致远，进一步巩固了行业龙头地位。展望未来，公司将继续坚守匠心、深耕主业，持续优化产品矩阵、深化科技赋能、拓展全球市场，以更优质的产品、更高效的服务、更强劲的创新力，守护中国味道、引领行业升级，书写中国调味品企业全球化高质量发展的崭新篇章。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

RESULTS HIGHLIGHTS:- The Revenue for the year ended 31 December 2025 was approximately HK$3,736.5 million, representing an increase of approximately 11.1% as compared with the same period last year.- The Gross Profit Margin for the year ended 31 December 2025 was approximately 55.8%; the gross profit was approximately HK$2,085.0 million, representing an increase of approximately 15.9% as compared with the same period last year.- The Group’s EBITDA for the year ended 31 December 2025 was approximately HK$938.1 million, representing an increase of approximately 32.4% as compared with the same period last year.- The Group’s net profit for the year ended 31 December 2025 was approximately HK$601.2 million, representing an increase of approximately 47.7% as compared with the same period last year.- Basic earnings per share for the year ended 31 December 2025 amounted to approximately HK63.7 cents, representing an increase of approximately 47.5% as compared with the same period last year.- The Board recommended the payment of a final dividend of HK15.0 cents per ordinary share for the year ended 31 December 2025.- For the year ended 31 December 2025, the Group recorded approximately 1,039,000 cases digital solution cases produced from the Group’s production facilities in Mainland China, Thailand and Vietnam, reflecting an increase of 32.7% as compared with the same period in 2024 as a result of our clients’ continued adoption of intra-oral scanners.HONG KONG, Mar 27, 2026 - (ACN Newswire via SeaPRwire.com) - 26 March 2026, Modern Dental Group Limited (“Modern Dental” or “the Group”, stock code: 03600.HK), a leading global dental prosthetic device provider, announces its annual results for the year ended 31 December 2025 (“the year”).During the year ended 31 December 2025, the Group’s multi-dimensional strategies and continuous enhancement of operational efficiency and productivity as supported by the ongoing trend of digitalization in the dental industry have resulted in the Group reporting record revenues, net profit and EBITDA numbers during this period. This occurred in a period of challenging macro-economic environment with general softness in demand for dental procedures and trade war uncertainties. The Group has been proactive in its approach to deal with the unprecedented international trade environment leveraging its international production facilities located in Thailand, Vietnam and Mainland China.The global digitalization trend continues to drive consolidation within the dental prosthetics industry, enabling the Group to further expand its market share. Our ongoing digital transformation initiatives are enhancing both customer and patient experiences while improving operational efficiency, further differentiating the Group from competitors and positioning us to outperform industry peers. The Group’s underlying fundamentals remain solid, and we are well positioned to capitalize on emerging opportunities going forward.European BusinessesDuring the year ended 31 December 2025, the European market recorded a revenue of approximately HK$1,887.0 million, representing an increase of approximately HK$268.0 million as compared with the year ended 31 December 2024. This geographic market accounted for 50.5% of the Group’s total revenue. The increase of revenue from the European market was mainly attributable to the increase in sales order volume driven by the launch of new products, such as digital dentures, and our state-of-the-art digital workflows.The Group has been the frontrunner to provide comprehensive digital solutions offerings, ranging from numerous minimal invasive and aesthetic prosthetic solutions to intra-oral scanners and clear aligners, and is well positioned to capture the opportunities arising from the accelerated digitalization trend of the dental industry. The Group continues to aggressively gain market share from international and domestic competitors through our established dental ecosystem solutions with a focus on education and digitalization, which is available within close proximity to our clients; effectively meeting our clients’ high expectations through our various onshore and offshore resources. The Group is committed and will continue to equip ourselves to provide the state-of-the-art digital solutions offerings to the dental community in the market.North American BusinessesDuring the year ended 31 December 2025, the North American market recorded a revenue of approximately HK$696.4 million, representing a decrease of approximately HK$55.7 million as compared with the year ended 31 December 2024. This geographic market accounted for approximately 18.6% of the Group’s total revenue.A significant portion of our business in the North America region comprises higher-end products manufactured domestically by MicroDental Laboratories, Inc. and its subsidiaries (“MicroDental Group”). While demand for discretionary cosmetic treatments remained soft throughout 2025, our centralized digital workflows and network-wide production oversight enabled us to deliver enhanced service quality and operational efficiencies to our North American customers.Our diversified supply bases in the US, China, Vietnam and Thailand continue to provide greater flexibility to navigate US tariff uncertainties — an advantage that sets us apart from competitors. Although digitalization of imported product lines drove growth in mass market cases, implementation of the US tariff in April 2025 introduced new uncertainties and contributed to a slow growth in sales for our import-focused business unit.Greater China BusinessesFor the year ended 31 December 2025, the Greater China market recorded a revenue of approximately HK$615.4 million, representing a decrease of approximately HK$46.8 million as compared with the year ended 31 December 2024. This geographic market accounted for approximately 16.5% of the Group’s total revenue.The Mainland China market faced headwinds from the volume-based procurement policies and a prolonged period of intense price competition and the situation started to stabilize in the second half of 2025. This also led to aggressive promotions for dental implant treatments by Mainland China dental clinics in Hong Kong (which experienced a notable decrease in patient visits in Hong Kong). The Group’s has deliberately pivoted away from low-margin segments and stay focused on serving mid- and high-value customers, ensuring long-term sustainable profitability of the Group’s business.The Group is optimistic in its mid/long-term outlook for this market in particular where the latest procurement-related government measures are expected to (i) standardize the pricing of dental prosthetics and develop price transparency, which would level the playing field; (ii) allow the Group’s leading brand name and reputation to be a key consideration for its client and customer; and (iii) have the Group benefit from its large production team and its ability to allocate resources efficiently according to the customer or client.Australian BusinessesFor the year ended 31 December 2025, the Australian market recorded a revenue of approximately HK$289.1 million, representing an increase of approximately HK$24.4 million as compared with the year ended 31 December 2024. This geographic market accounted for approximately 7.7% of the Group’s total revenue. The increase in revenue from Australia reflected a strong uptake of new digital products driven by the digitalization trend in dental industry and the revenue contribution from the acquisition of Digital Sleep which is partially offset by the depreciation of AUD against HK$ by 2.4% compared with the year ended 31 December 2024.Through our various brands, which offer onshore-and offshore-made products, at multiple price points ranging from economy and standard to premium/boutique, the Group is able to effectively penetrate the entire Australian market. We have invested in local production capacity to provide faster service to our customers, and to provide choices around where the products are made. The Group is one of the largest players in the Australian market and is a preferred supplier to the major corporate dental groups in the market.Other MarketsOther markets primarily include Thailand, Indian Ocean countries, Malaysia, Taiwan and Singapore. For the year ended 31 December 2025, these markets recorded a revenue of approximately HK$248.9 million, representing an increase of approximately HK$182.4 million as compared with the year ended 31 December 2024. This geographic market accounted for approximately 6.7% of the Group’s total revenue. The increase in revenue from Other markets was primarily driven by the revenue contribution from the newly acquired Hexa Ceram.Future Prospects and StrategiesThe global macroeconomic environment remains uncertain, with geopolitical tensions and potential tariff changes continuing to create headwinds. However, the Group’s geographically diversified production footprint and global distribution network position us strongly to navigate these challenges. Unlike many competitors reliant on single-country manufacturing, our operations across China, Vietnam and Thailand (including the newly acquired Hexa Ceram) provide superior resilience and flexibility. This strategy, combined with our ability to adapt quickly to local market conditions, enables the Group to mitigate risks and capitalize on opportunities across regions.The dental industry has continued to demonstrate remarkable resilience, underpinned by irreversible demographic trends, including aging populations and increasing awareness of oral health, which drive consistent long-term demand. Building on our record 2025 performance, the Group is well placed to sustain momentum and further strengthen its market leadership.Digitalization remains an irreversible industry trend that is accelerating consolidation of the dental prosthetics industry. We are at the forefront of this transformation, with digital solution cases now representing approximately 35–40% of total volume. Our centralized digital workflows, intra-oral scanner partnerships, proprietary solutions and global education centers have enhanced operational efficiency, reduced turnaround times and delivered superior customer experiences. These initiatives create high entry barriers and will continue to drive margin expansion and market share gains in the coming years.Following the successful integration of Hexa Ceram (Thailand’s largest dental laboratory, acquired in January 2025) and Digital Sleep Design (Proprietary nylon oral appliance to treat obstructive sleep apnea), our Southeast Asian presence and specialized capabilities have been significantly strengthened. This expansion, coupled with our diversified supply bases in the US, China, Vietnam, and Thailand, provides enhanced flexibility to address potential trade and geopolitical risks while supporting faster regional delivery.Looking ahead, the Group remains committed to reinforcing its worldwide leading position through a multi-dimensional approach. We will continue to pursue selective acquisitions, joint ventures and partnerships to expand and complement our product offerings, particularly in our high-growth clear aligner, Trioclear, while strengthening our distribution and sales networks. Ongoing investments in mass-scale production facilities, AI, automation, research and development, and digital innovation will drive efficiency gains and secure our position at the forefront of the industry.About Modern Dental GroupModern Dental Group Limited (Stock code: 03600.HK) is a leading global dental prosthetics provider, distributor and consultant with a focus on providing custom-made prostheses to customers in the growing prosthetics industry. Our product portfolio is broadly categorized into three product lines: fixed prosthetic devices, such as crowns and bridges; removable prosthetic devices, such as removable dentures; and other devices, such as orthodontic devices, sports guards, clear aligners, and anti-snoring devices. Modern Dental Group has a global portfolio of respected brands, including Labocast, Permadental and Elysee Dental in Western Europe, YZJ Dental in China, Modern Dental Lab in Hong Kong, Modern Dental USA and MicroDental in the United States, Modern Dental Pacific in Australia and New Zealand, Modern Dental SG in Singapore, Modern Dental TW in Taiwan, Apex Digital Dental in Malaysia and Hexa Ceram in Thailand. We have grown these brands by providing premium and consistent quality products and superior customer service. We have more than 80 service centers in over 28 countries and serve over 35,000 customers. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

业绩摘要：- 截至2025年12月31日止年度收益约为37.4亿港元, 同比增加约11.1%。- 截至2025年12月31日止年度毛利率约为55.8% ；毛利约为20.8亿港元，同比增加约15.9%。- 截至2025年12月31日止EBITDA 约为9.4亿港元，同比增加约32.4%。- 本集团于截至2025年12月31日止纯利约为6.0亿港元，同比增加47.7%。- 截至2025年12月31日止每股基本盈利约为63.7港仙，相较去年同期增加约47.5%。- 董事会建议宣派截至 2025年12月31日止年度末期股息每股普通股15.0港仙。- 截至2025年12月31日止年度，本集团于中国内地、泰国及越南生产设施生产之数码化解决方案个案增加至约1,039,000件，较2024年同期增加32.7%，原因为更多客户采用口腔内部扫描仪。香港, 2026年3月27日 - (亚太商讯 via SeaPRwire.com) - 2026年3月26日，全球领先之义齿器材供应商 - 现代牙科集团有限公司 (简称「现代牙科」或「本集团」，股份代号：03600.HK) 欣然公布截至2025年12月31日止年度(「年度」) 业绩。截至2025年12月31日止年度，在牙科行业数码化趋势持续的支持下，本集团的多维度策略及持续提升的营运效率及生产力，使其于本期间的收益、纯利及EBITDA数字均创下纪录新高。虽然期内宏观经济环境充满挑战，牙科手术的需求普遍疲弱，且贸易战存在不确定性，然而仍然创下纪录。本集团利用位于泰国、越南及中国内地的国际生产设施，积极应对前所未有的国际贸易环境。全球数码化趋势持续推动义齿行业的整合，使本集团进一步扩大其市场份额。我们持续的数码转型措施提升客户及病人体验的同时，进一步使本集团在竞争对手中脱颖而出，表现优于同业。本集团的相关基础仍然稳固，并将全力以赴把握未来机遇。欧洲市场业务截至2025年12月31日止年度，欧洲市场录得收益约18.9亿港元，较去年增加约2.7亿港元，此地理市场占本集团收益总额50.5%。欧洲市场收益增加主要由于新产品的推出(例如数码化义齿)及我们最先进的数码化流程，推动销售订单量增加。本集团已成为提供全面数码化解决方案的先驱，范围涵盖多项微创及美容义齿解决方案以至口腔内部扫描仪及透明矫正器，本集团已准备好把握牙科行业数码化趋势加速带来的机遇。本集团继续透过所建立，重点为教育及数码化且非常邻近客户的牙科生态系统解决方案，积极从国际及本地竞争对手取得市场份额；透过不同的境内及境外资源有效地满足我们客户的高期望。本集团一直致力并将继续装备好自己，为市场上的牙科领域提供最先进的数码化解决方案。北美市场业务于截至2025年12月31日止年度，北美市场录得收益约7.0亿港元，较去年减少约5,570万港元，此地理市场占本集团收益总额约18.6%。我们在北美地区的大部分业务包括MicroDental Laboratories, Inc.及其附属公司(「MicroDental集团」)在本地制造的高端产品。虽然2025年对主动美容治疗的需求仍然疲弱，然而我们的中央化数码流程及对区内广泛生产单位的网络让我们为北美客户交出更高服务质素及营运效率。我们位于美国、中国、越南及泰国等地的多元化供应基地，继续在应对美国关税的不确定性时带来更大弹性－此为将我们与竞争对手作区分的优势。虽然进口产品线的数码化带动大型市场个案的增长，然而2025年4月在美国实施的关税带来新的不确定性及为我们以进口为主的业务单位的销售带来缓慢增长。大中华市场业务截至2025年12月31日止年度，大中华市场录得收益约6.2亿港元，较去年减少约4,685万港元，此地理市场占本集团收益总额约16.5%。中国内地市场面对带量采购政策及价格激烈竞争延长的逆境，而于2025年下半年情况开始稳定。此亦导致中国内地牙科诊所积极于香港推广种植牙治疗(香港患者就诊人数明显减少)。本集团有意退出低利润分部，并专注于中及高价值客户，确保本集团业务能够长期及可持续获利。本集团对此市场的中长期前景感到乐观，特别是在政府最新的采购相关措施中，预计(i)规范义齿价格及建立价格透明度，平衡中心点；(ii)让本集团领先的品牌名称及声望成为客户及顾客的主要考虑；及(iii)让本集团从其庞大生产团队中得益及根据顾客或客户有效分配资源的能力。澳洲市场业务截至2025年12月31日止年度，澳洲市场录得收益约2.9亿港元，较去年增加约2,438万港元，此地理市场占本集团收益总额约7.7%。澳洲的收益录得增长，反映牙科行业数码化趋势带动大量新的数码化产品，以及收购Digital Sleep的收益贡献，但部分被相较于截至2024年12月31日止年度，澳元兑港元贬值2.4%所抵销。透过我们不同的品牌(可提供境内及境外制造的产品)，凭借涵盖从经济及标准至优质/精品等的多种价位，本集团能够有效地渗透整个澳洲市场。我们投资于本地产能，以为客户提供更快捷的服务，并可供选择产品之生产地。本集团为澳洲市场最大参与者之一并为市场内主要企业牙科团体的首选供应商。其他市场其他市场主要包括泰国、印度洋国家、马来西亚、台湾及新加坡。截至2025年12月31日止年度，该等市场录得收益约2.5亿港元，较截至2024年12月31日止年度增加约1.8亿港元。此地理市场占本集团收益总额约6.7%。其他市场的收益增加主要由于新收购的Hexa Ceram带来的收益贡献所致。未来前景及策略全球宏观经济环境仍然不明朗，地缘政治的紧张局势及关税的潜在变动继续营造不利环境。然而，本集团的生产遍及全球各地，而全球分销网络让我们在面对该等挑战时享有独特优势。有别于依赖单一国家生产的一众竞争对手，我们的营运遍布中国、越南及泰国(包括新收购的Hexa Ceram)等地，让我们面对挑战时能够进退有据，灵活应变。此策略连同我们快速适应当地市场环境的能力，使本集团降低风险，同时把握各地区的新兴机遇。牙科行业继续展现卓越的适应力，在不可逆转的人口趋势下加以突显，包括人口老化及人们对口腔健康的意识提高，持续带动义齿的长期需求。本集团建基于2025年创记录的表现而处于有利位置，能够保持良好势头，同时进一步强化市场的领导地位。行业数码化势不可挡，加快义齿行业的整合。我们处于转型的尖端，目前数码化解决方案个案占总销量约35至40%。我们的中央化数码工作流程、有关口腔内部扫描仪的伙伴关系、专有的解决方案及全球教育中心有助提升营运效率、缩短处理时间及提供卓越的客户体验。有关措施创造高进入门槛，并将于未来数年继续扩大利润及增加市场份额。在成功整合于2025年1月收购的泰国最大牙科实验室Hexa Ceram及Digital Sleep Design(用于治疗阻塞性睡眠窒息症的专利尼龙口腔矫正器)后，我们在东南亚地区的影响力及专业能力已经大幅提升。是次扩张连同我们位于美国、中国、越南及泰国等地的多元化供应基地，让我们在应对潜在的贸易及其他地缘政治风险时带来更大弹性，同时支持区内快速交付。展望将来，本集团仍然致力透过多角度方针强化其全球领导地位。我们将继续寻求具针对性的收购、合营企业及伙伴关系，以扩大及补充我们所提供的产品，特别是我们高增长的透明矫正器TrioClear，同时加强我们的分销及销售网络。我们在大型生产设施、AI、自动化、研发及数码创新方面的持续投资，使效率大幅增高，从而确保我们一直处于行业尖端。关于现代牙科集团现代牙科集团有限公司 (股份代号: 03600.HK) 为全球领先的义齿器材供应商、经销商和顾问，专注于发展迅速的义齿行业为客户提供定制式义齿。我们的产品组合大致可分为三类﹕固定义齿器材，例如牙冠及牙桥；活动义齿器材，例如活动义齿；及其他器材，例如正畸类器材、透明牙套、运动防护器及防鼾器。 现代牙科集团拥有多个备受称许的全球品牌，包括西欧的Labocast、Permadental及Elysee Dental、中国的洋紫荆牙科器材、香港的现代牙科器材、美国的Modern Dental USA及MicroDental、澳洲及新西兰的Modern Dental Pacific、新加坡的Modern Dental SG、台湾的 Modern Dental TW、马来西亚的 Apex Digital Dental及泰国的Hexa Ceram等。我们提供稳定和优质的产品及卓越的客户服务，令这些公司品牌能茁壮成长。我们于全球超过 28个国家拥有超过 80 家服务中心及服务逾 35,000 名客户。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HIGHLIGHTS:- Total gross billings amounted to approximately RMB3,955.0 million, representing an increase of approximately 12.8% from approximately RMB3,505.9 million for the corresponding period.- Total revenue was approximately RMB3,430.1 million, representing an increase of approximately 48.7% from approximately RMB2,306.0 million for the corresponding period.- The profit attributable to Shareholders of the Group was approximately RMB921.8 million, representing an increase of approximately 238.5% from approximately RMB272.4 million for the corresponding period.- Non-HKFRS adjusted profit for the year (excluding the share-based compensation expenses) was approximately RMB1,022.5 million, representing an increase of approximately 191.8% from approximately RMB350.5 million for the corresponding period.- Taking into account the financial and cash flow positions of the Group, the Board recommends the payment of a final dividend of approximately HKD168.5 million for the year ended December 31, 2025, representing HKD0.36 per share (in cash), and the proposed final dividend is subject to consideration and approval by Shareholders at the AGM.HONG KONG, Mar 27, 2026 - (ACN Newswire via SeaPRwire.com) - JF SmartInvest Holdings Ltd (the “Company” ; together with its subsidiaries, the "Group" or “we”) is pleased to announce its consolidated annual results for the year ended December 31, 2025 (the “Reporting Period”). During the Reporting Period, leveraging its “technology + investment research” dual-drive strategy, the Group achieved outstanding performance. Supported by robust cash flow and profitability, the Board has proposed a final dividend of HK$0.36 per share, bringing the total dividend for the full year to approximately HK$407.4 million when combined with the interim dividend already paid, reflecting its commitment to delivering returns to shareholders.Strong Financial Performance with Substantial Profitability ImprovementDuring the Reporting Period, the Group continued to advance product innovation, AI applications, and investment research capabilities, driving solid growth across its business. Total revenue for the year reached RMB3,430.1 million, representing a YOY increase of 48.7%. Gross profit amounted to RMB2,821.0 million, up 48.9% YOY, while the gross profit margin remained at a high level of 82.2%, indicating the favourable economies of scale and earnings quality of the Group’s business model.In terms of profitability, profit attributable to equity shareholders surged by 238.5% YOY to RMB921.8 million. Excluding share-based compensation expenses, non-HKFRS adjusted profit for the year reached RMB1,022.5 million, representing a YOY increase of 191.8%, fully demonstrating the effective strategy execution and market adaptability of the Group.The Group places great emphasis on shareholder returns. The Board recommends the payment of a final dividend of approximately HKD168.5 million for the year ended December 31, 2025, representing HKD0.36 per share (in cash). Together with the interim dividend of approximately HK$238.9 million already distributed, the total dividend for 2025 will amount to approximately HK$407.4 million. The steady dividend policy fully reflects the Group’s ample cash reserves and its firm confidence in future development prospects.Continued Optimisation of Product Matrix and Enhancement of Diversified Service SystemDuring the Reporting Period, the Group continued to build a diversified product matrix, enriching its product portfolio in response to different customer needs. VIP products 'Stock Navigator, Super Investor' were steadily optimized, with the addition of several quantitative products and AI-powered products. We also launched a 24/7 AI intelligent customer service system, which significantly improved service efficiency. The live streaming system was upgraded, with sessions increasing by 36% YOY and average daily unique viewers exceeding 100,000.Relying on an integrated “AI + content + service + tools” solution, the Enjoy-Stock Pad recorded net sales volume exceeding 75,000 units during the Reporting Period. The Jiuyao Stocks launched over 80 lightweight products, converting professional investment research capabilities into standardised products. The SmartInvest APP completed its strategic transformation from a tool to a platform, with monthly active users increasing by more than 40% YOY and the 30-day retention rate remaining above 50%.The Group further enhanced its product matrix with two new products, Decision Master and Star-tier Services, filling the gap in the mid-tier product system and enabling a seamless trading service experience. Decision Master focuses on three AI+ investment research modules - themes, value investing and quantification - comprehensively enhances investment decision-making capabilities of individual investors. Star-tier Services collaborates with multiple securities brokerages and partners to create a fully integrated closed-loop ecosystem of“tools-services-trading”, serving over 50,000 users during the Reporting Period.Guided by Technological Innovation, Striving Towards “Investment Advisory Intelligent Agent 2.0”The Group regards innovation and technological R&D as its core driving force, accelerating its transformation towards “digital intelligence”, and advancing towards the era of “investment advisory intelligent agent 2.0”. During the Reporting Period, R&D expenses amounted to approximately RMB356 million, with R&D personnel reaching 624, a YOY increase of approximately 42.8%. The Group held 158 software copyrights and patents in AI, big data and product features, with 22 new items added on a year-on-year basis.The self-developed FinSphere Agent Large Model Assistant V3.0 passed the Large Model Assistant Functionality Completeness Test conducted by the China Academy of Information and Communications Technology, becoming the first large-model application in the securities industry. During the Reporting Period, it served approximately 664,000 customers with cumulative services of 22.58 million. The digital intelligent investment robo-advisor “Jiu Ge” served approximately 600,000 customers with cumulative services exceeding 19 million. The Group also launched stock diagnosis intelligent agent 4.0, AI Xiaoce Q&A assistant, and established an intelligent compliance and risk control platform covering the entire business workflow, indicating that the group's AI capabilities have gradually been implemented in core scenarios.To strengthen its technological foundation, the Group established a technology subsidiary, Jiufang Zhiqing, and set its foothold in “Shanghai Foundation Model Innovation Center”, China’s first large model innovation ecosystem community. The subsidiary serves as the Group’s core AI vehicle for operating a native service technology system, promoting the deep application of AI in scenarios such as investment research, investor education, and risk control.Deep-Rooted Investment Research as the Cornerstone, Adhering to Buyer-Side Advisory and Deepening the “1+N” Investment Research SystemThe Group continues to deepen its “1 research institute and N business lines” investment research system, with the JF Financial Research Institute as investment research hub. The Institute has established a pyramidal-structured professional talent echelon led by Chief Economist Dr. Xiao Lisheng, comprising 4 experts, 8 super-IPs and 128 professionals. As of the end of the Reporting Period, the Group had 576 employees holding securities investment advisory qualifications and 2,628 employees holding securities practitioners, maintains a leading team scale and structure in the industry.During the Reporting Period, The Institute conducted more than 300 research activities, covering more than 2,000 listed companies. The Institute authored approximately 1,200 in-depth research reports and 45 sets of thematic courses with a total duration of 2,000 minutes, continuously enhancing the professional capabilities of buyer-side consultants.Multi-Dimensional, Full-Funnel Traffic Operation to Unlock New Growth DimensionsDriven by AI technology, the Group positions refined MCN-based traffic operations as a central hub connecting users with its business, building an integrated, synergistic omni-channel traffic ecosystem comprising “public-domain MCN (multi-platform) + private-domain + proprietary APP”. On the technological front, the Group applied AIGC to restructure content production, shifting from manual creation to “human-machine collaboration” model, and established a data flywheel integrating “advertising data, model training and operational automation”. During the Reporting Period, the Group consolidated its leading position on online short-video and live streaming platforms’ operations, established a multi-platform coordinated traffic matrix, and developed a multi-tiered, high-quality content ecosystem. It also pioneered e-commerce models for the Enjoy-Stock Pad and AppStore models for the APP, driving deep integration between traffic operations and product features.Future OutlookMr. Chen Wenbin, chairman of the Board and chief executive officer of JF SmartInvest Holdings Ltd, said: “In 2025, we remained committed to the dual-drive strategy of ‘technology + investment research’. Not only did we achieve leapfrog growth in performance, but we also successfully led the industry into the era of ‘Investment Advisor Agent 2.0’. Leveraging artificial intelligence and big data technologies, we developed AI products such as the JF Robo-Advisor, FinSphere Agent and FinSphere Report, achieving industry-leading innovations and scenario-based applications, helping users accomplish the critical transition from ‘cognitive improvement’ to ‘decision optimisation’. At the same time, we transformed our professional investment research capabilities into easily accessible lightweight services, realising a strategic shift ‘from tool to platform’. We uphold the principles of rational investing, value investing and long-term investing, assisting clients in developing sound investment philosophies.“In the future, the Group will focus on four key strategic dimensions. First, deepening AI-driven empowerment across all scenarios, accelerating the iteration of AI agents and their commercialisation on the consumer side, and driving the Group’s digital and intelligent transformation. Second, leveraging Forthright Securities and Forthright Capital’s licenses, advancing the globalisation strategy by exporting the Jiufang’s core models, accelerating overseas business expansion. Meanwhile, promoting license upgrading and strategic investment layout to further improve the construction of digital asset infrastructure. Third, strengthening product-driven business diversification and synergies, deepening cooperation with licensed financial institutions such as securities brokerages, and building a service closed loop covering pre-investment, in-investment and post-investment. Fourth, continuing to optimize the customer operation system, unlocking the value of traffic through full-funnel traffic initiatives, and achieving long-term customer retention. We are dedicated to making investing simpler and more professional while enhancing investors’ sense of fulfillment in investment and wealth management.”About JF SmartInvest Holdings Ltd (Stock Code: 9636)JF SmartInvest Holdings Ltd is a new generation stock investment assistant. The Company is engaged in the provision of equity investment instruments, securities investment advisory, investor education and other services to individual investors. The products include stock quote software, the AI Stock Machine, Stock Navigator, Super Investor and Jiuyao Stocks. The Company adopts the technology + investment research model, develops JF Robo-Advisor, FinSphere Agent, FinSphere Report and other products based on artificial intelligence (AI) and big data technology, which are applied to the industry in terms of innovative practice and scenario application.For enquiries, please contact:Financial PR (HK) LimitedEmail: ir@financialpr.hkTel: 852 2610 0846Fax: 852 2610 0842 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

SINGAPORE, Mar 27, 2026 - (ACN Newswire via SeaPRwire.com) - Choosing where to place your savings in Singapore is an important financial decision that requires careful consideration. With many banks offering different types of accounts, it is easy to get confused. However, picking the right one is the first step to reaching your financial goals, whether you are saving for a dream wedding, a new home, or a retirement fund.The good news is that you no longer need to spend a whole afternoon waiting at a bank branch. You can now open a bank account online in just a few minutes using your phone or computer. Here is a simple guide to help you choose the best account for your needs in 2026.Identify Your Financial HabitsBefore focusing on interest rates, consider how you manage your money on a daily basis. Savings accounts in Singapore usually fall into two categories:The Active Saver: These accounts give you high interest rates, but you have to make a few mandatory transactions each month. Usually, you need to credit your salary and spend a set amount on your credit card.The Passive Saver: These accounts help you earn bonus interest just for keeping your money in the account and letting it grow. You do not need to worry about credit card spending or paying bills.Compare Interest RatesBefore opening a bank account online, make sure you compare the interest rates. Many basic accounts offer low interest rates. To make your money grow, you should look for bonus interest.For example, a high-interest account can offer between 2% and 5% depending on the rules you follow. If you have SGD 50,000, the difference between a basic account and a high-interest one could be hundreds of dollars in extra cash every year. Always check the effective interest rate, which tells you the real amount you will earn after all the levels are counted.Look for Welcome PromotionsBanks in Singapore are always competing for your business. When you open a bank account online, you can often grab a welcome gift, such as cash credits or rewards. These promotions are a great way to get a head start on your savings. Just make sure to check the dates, as many of these flash deals only last for a few months.Check the Fees and MinimumsEven a great account can lose you money if you are not careful about fees. Before you sign up, check for these three things:Minimum balance: Most accounts require maintaining a certain amount of money in the account at all times. If the balance drops below this limit, the bank may charge you a monthly fee.Initial deposit: Some accounts require at least SGD 1,000 to get started.ATM access: Make sure the bank has plenty of ATMs near your home or office so you do not get charged for using the machine of another bank.Open an Account OnlineOnce you have picked the right account, the final step is to fill out your application. In Singapore, you can use Singpass MyInfo to fill out your application automatically.When you open a bank account online, your details, such as your NRIC, address, and income, are pulled directly from the government database, thus reducing paperwork. Most accounts are approved almost instantly, and you can start using your new digital card right away.Final ThoughtsChoosing a savings account is not just about finding the highest interest rate. It is about finding the one that fits how you live. If you are a busy professional who already uses a credit card, an active account is perfect. If you just want to set your money aside and forget it, a passive account is better.By taking 10 minutes to compare your options today, you can ensure that every dollar you earn works as hard as you do.Disclaimer: This article is for general information only and does not have any regard to the specific investment objectives, financial situation and particular needs of any specific person. The views expressed in this article are solely those of the author. This article shall not be regarded as an offer, recommendation, solicitation or advice. You may wish to consult your own professional advisers about this article, in particular, a financial professional before making financial decisions. Any past events, trends and/or performance referred to in this article may not necessarily be indicative of future events, trends or performance. This article is based on certain assumptions and reflects prevailing conditions as at the time of publication, which are subject to change at any time without notice. The author and publisher of this article as well as any other parties associated with this article make no representation or warranty of any kind, whether express, implied or statutory, in respect of this article and accept no liability or responsibility for the completeness or accuracy of this article or any error, inaccuracy or omission relating to this article and/or any consequence, injury, loss or damage howsoever suffered by any person relating to this article, in particular, arising from any reliance by any person on this article. Publishers or platforms may be compensated for access to third party websites.Contact Information:Name: Sonakshi MurzeEmail: Sonakshi.murze@iquanti.comJob Title: ManagerSOURCE: iQuanti Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

近日，2026中关村论坛年会在北京隆重举行。作为国家级科技创新交流合作平台的重要参与者，百望股份受邀出席本次国家级科技创新交流盛会，并在"东盟创新合作发展论坛"中发表了重磅主题演讲。论坛上，百望股份聚焦跨境贸易合规痛点，推介全球智能税务合规平台Tax Swift。它内置百望自研的AI税务引擎、百望指数与国家适配器，依托覆盖全球的税务规则知识库，动态监控、AI分析、自动更新，打造起全球贸易的"合规路由器"，为国际经贸合作注入合规新动能。论坛聚焦科技创新，跨境合规成全球贸易核心命题2026年中关村论坛年会，是经国务院批准、以"科技创新与产业创新深度融合"为年度主题，由科技部、国家发展改革委、工业和信息化部、国家国资委、中国科学院、中国工程院、中国科协和北京市政府共同主办。大会汇聚了100多个国家和地区的全球顶尖科学家、企业家及国际组织代表，上千名嘉宾共同搭建起中国与世界科技创新交流的桥梁。作为本次中关村论坛的重要平行论坛，东盟创新合作发展论坛聚焦中国与东盟科技创新协同、产业融合发展、跨境贸易便利化等核心议题，汇聚东盟各国政、产、学、研各界代表，交流研判破解区域经贸合作中的共性难题。在主题演讲环节，百望股份围绕着"AI赋能中企出海：构建全球化合规新底座"展开了深度分享。当前，全球贸易一体化进程不断加快，跨国经营的业务蓬勃发展，但税务合规难题始终是制约全球贸易高效推进的关键瓶颈。尤其是东盟这样的活力经济体，区域内各国经贸往来频繁，跨境交易规模持续攀升，市场主体对于交易效率、交易合规有着更高的需求和更迫切的期待，而区域内各国税务政策、技术标准的差异，却成为了制约中国-东盟跨境贸易提质增效的重要因素。从实践来看，国际贸易税务合规难题呈现多元化、复杂化态势：- 语言与格式壁垒凸显，不同标准、规范让企业票据解读成本高、理解易出偏差；- 各国财税政策碎片化严重，差异性的税种、税率、申报流程，让企业难以精准掌握；- 技术标准不统一，系统接口、数据传输缺乏规范，各类操作繁琐且效率低下；- 跨境交易链条长、涉及主体多，企业难以实现全流程风险检测；这些难题不仅增加了企业跨境经营的成本，更成为制约企业融入全球产业链、拓展国际市场的关键瓶颈。百望股份的Tax Swift平台，正是破解合规困境、保驾跨境贸易的全新技术创新，尤其为中国-东盟跨境贸易合规发展提供了高效可行的思路。Tax Swift重磅亮相，全链路一站式赋能国际贸易合规作为百望股份的深耕全球税务合规领域、布局国际化市场的核心成果，Tax Swift一次适配，就可帮助企业构建起覆盖"票据处理-纳税申报-风险管控"的全链路跨境税务合规服务体系：一是全球AI全链路票据处理能力，可打破语言与格式壁垒。国际化引擎、发票引擎、税务引擎与国家适配器，四重引擎自动协同运转，完成智能算税、智能识别等，一套架构适配全球业务场景。企业无需手动干预任何细节，即可完成多语言、多币种、多时区的票据管理工作，完美适配东盟各国票据规范与业务场景。二是全球AI一键申报，打通跨境税务申报便捷通道。Tax Swift现已与20多国国税局直连，全球税务规则知识库动态更新、AI分析引擎自动扫描规则变化，联动发票识别引擎与全球交易计税规则引擎实时响应，将全球申报工作压缩成一个动作：一键登录，自动填饱，实时同步状态，可大幅提升东盟跨境贸易税务申报效率。三是全球AI税务顾问，提供全周期政策支撑。平台内置超3万条国际财税规则，覆盖200+国家税种与费金，通过实时联动发票引擎与税务引擎，实现AI自动解读、自动更新，及时识别和处置异常变化，帮助企业精准把握区域政策动态、规避合规风险，尤其针对东盟各国税务政策的更新与调整实现实时响应。三大AI能力模块的协同运作，为企业建立起全球合规洞察的能力，构筑起清晰可控的合规管理边界。当前，全球贸易格局深度调整，合规已成为企业跨境经营的核心竞争力，百望股份"贸易无国界、纳税有主权"的理念，精准契合了出海企业的合规需求。依托全球化战略布局，百望股份持续推进TaxSwift产品迭代落地，自2025年8月启动以来，产品已完成1.0版本全球电子发票布局，并在2026年加速海外数据中心与算力中心部署，加速东南亚、欧盟、中东等区域市场的拓展，向着建设覆盖80+CTC国家的全球AI票税合规平台快速演进。而东盟作为百望股份全球化出海的先锋阵地，凭借区域内旺盛的跨境贸易合规需求，成为 Tax Swift 落地应用的核心市场，已有众多企业与百望股份达成深度合作，其中越南、新加坡、印度尼西亚等东盟国家的企业、高校更是与百望携手，共同探索跨境税务合规的数智化解决方案，让 Tax Swift的技术能力与服务体系更好地适配东盟市场需求。依托中关村论坛及东盟创新合作发展论坛的开放平台，更多国际嘉宾尤其是东盟各国代表，对百望股份的数智解决方案有了进一步了解。深耕财税数智领域十余年，百望股份已经累计处理发票数量逾260亿张，对应交易总额高达1188.0万亿元，服务的纳税人识别号数量更是突破了9640万家，这些丰富的实践经验与数据智能领域的深厚沉淀，赢得了与会嘉宾产生了高度关注与广泛认可。未来，百望股份将持续深化Tax Swift平台的迭代升级，重点打磨适配东盟市场的产品能力与服务体系，打造一流的全球税务合规智能体平台，进一步拓展全球服务范围，帮助更多跨境经营的国际企业开拓发展、赢得未来！ Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

- Annual sales of HuaTangNing exceeded 4 million packs, a year-on-year increase of 91%, with revenues reaching RMB 492.9 million, a year-on-year increase of 93%, marking outstanding results from the Company’s fully independent commercialization operation.- Delivered record financial performance, with profit before tax reaching RMB 1,106.4 million; maintained a robust bank balance and cash position of RMB 1,092.3 million at year-end, laying a solid foundation for sustainable operations and growth.- Gross margins rose to 56.9%, and selling expenses as a percentage of revenue were optimized to 33.6% from 59.9%, significantly enhancing profitability.- HuaTangNing renewed its listing in the new National Reimbursement Drug List (NRDL) at the same price in 2025 for the calendar years 2026 and 2027, reaffirming its clinical and innovative value.- With the approval of PTE, market exclusivity in China granted another 5 years to April 2034, further strengthening commercial certainty.- Dorzagliatin was approved for commercialization in Hong Kong as HYHOMSIS®, accelerating its global expansion toward South-East Asia.- Multiple real-world evidence published to demonstrate therapeutic advantage of dorzagliatin.- Continuous expansion of therapeutic potential of glucose homeostasis and initiation of new first-in-disease indications study covering diabetes prevention, rare diseases, mild cognition impairment and frailty.SHANGHAI, Mar 27, 2026 - (ACN Newswire via SeaPRwire.com) – Hua Medicine ("the Company", Hong Kong Stock Exchange Stock Code: 2552) announces the audited consolidated results of the Company and its subsidiaries for the year ended December 31, 2025 (the “Reporting Period”). During the Reporting Period, the commercialization of HuaTangNing (dorzagliatin tablets), the Company’s core product – the global first-in-class innovative anti-diabetes medicine, glucokinase activator (GKA) – advanced comprehensively across all fronts, the Company’s independent commercialization team was efficiently and seamlessly established in its first year of operations, the Company’s R&D pipeline continued to be enriched, and the Company’s financial performance achieved a historic breakthrough, successfully entering a new stage of profitability, injecting strong momentum into the innovative development of the global diabetes treatment field.Dr. Li CHEN, Founder and CEO of Hua Medicine, stated: “2025 is a remarkable year in the commercialization operation of Hua Medicine. The Company has successfully advanced from R&D to commercialization driven organization and achieved the fully independent capacity in commercialization of global first in class novel glucose homeostasis regulator HuaTangNing. With strong market execution and product competitiveness, we have achieved nearly triple-digit growth in sales volume and revenue over 2024 when the commercialization was farmed out to sales and marketing partners. At the same time, the Company has made key progress in global market expansion through registration of drozagliatin in Hong Kong and position it toward 700 M population in south-east Asia. We continue to expand the clinical application of glucose homeostasis regulation technology and engage in new indications such as early-stage Alzheimer’s disease and Frailty. The first-in-disease efforts in GCK-MODY and Frailty set the new innovation course of Hua Medicine in the next 5 years.” Business Highlights and Operational Progress- Fully Powered Commercialization, Historic Breakthrough in ProfitabilityOn January 1, 2025, the Company assumed full responsibility for the commercialization of HuaTangNing, allowing the company to consolidate both operational and strategic control over market execution in China. The Company successfully built a professional sales team covering 10 sales regions around the country, focusing on marketing, medical affairs and commercial operation. Through an AI-empowered digital commercialization platform, operational efficiency and sales productivity were greatly enhanced, injecting new vitality into the Company’s commercial development.Reimbursement coverage under the NRDL has significantly increased accessibility, especially in Tier 2 and Tier 3 hospitals, and played a critical role in accelerating patient adoption. Since its launch in October 2022, HuaTangNing has been prescribed to over 500,000 patients through 3,000+ hospitals, community centers, pharmacies and online channels.Sales performance exceeded expectations, with 4.011 million packs of HuaTangNing sold during the reporting period, representing a 91% increase over the fiscal year 2024. This growth was achieved at the same price for both periods, underscoring strong demand and successful execution of Hua’s commercial strategy.In terms of profitability, the Company’s gross profit reached approximately RMB280.4 million, a year-on-year increase of 125%. Thanks to expanded production scale and optimized manufacturing processes, the Company’s gross margin improved to 56.9%, increasing by 8.2 percentage points as compared to 48.7% for the year of 2024. Selling expenses increased only by RMB12.3 million to RMB165.5 million, reflecting a significant positive trend towards profitability when our selling expenses in the 2025 fiscal year represents only 33.6% of revenue, whereas in the 2024 fiscal year, our selling expenses represented approximately 59.9% of revenue. In fiscal year 2025, our commercialization efforts achieved profits of approximately RMB114.9 million (as defined by gross profits less selling expenses). Although we expect to continue to increase personnel to our commercialization team, we expect this profitability trend in our commercial operations in mainland China to continue.Following the termination of the collaboration with Bayer at the end of 2024, dorzagliatin achieved a record-high sales volume. Profit before tax increased to RMB1,106.4 million for the fiscal year 2025. We ended fiscal year 2025 with a cash position of approximately RMB1,092.3 million.- Accelerated Global Layout, Strengthened Core Rights and InterestsThe Company took a key step in global expansion. On February 27, 2026, dorzagliatin (trade name: MYHOMSIS®, was successfully approved for marketing by the Hong Kong regulatory authority. The Company plans to officially launch the product in the Hong Kong market by the middle of 2026 and further expand to Asian regions. In addition, the Company submitted a new drug registration application in Macau in 2025.The Company also made new progress in intellectual property protection. In February 2026, the patent term extension (PTE) application for dorzagliatin was formally approved by the China National Intellectual Property Administration, thereby the core patent protection period of dorzagliatin extended to April 2034 and an additional 5-year market exclusivity obtained, which provides a strong guarantee for the product’s long-term market competition.In 2025, dorzagliatin was recognized as national innovation and an effective therapy for chronic diseases by the regulatory authorities in China. Accordingly, the same NRDL price was offered for the calendar years 2026 and 2027. Reimbursement coverage under the NRDL has significantly increased accessibility, especially in Tier 2 and Tier 3 hospitals, and played a critical role in accelerating patient adoption. The Company will continue to safeguard the product’s market competitiveness and patient accessibility and accelerate the popularization of the drug among patients.- Advancement of Real-World Studies, Continuous Validation of Clinical ValueReal-world evidence (RWE) studies continue to corroborate the key role of dorzagliatin in improving glucose-dependent pancreatic islet secretion function, and demonstrate its efficacy in diabetes prevention, remission, and delaying or preventing diabetes complications.The RWE study sponsored by Hua Medicine HMM0701 with 380 T2D patients was fully enrolled in 2025. The interim analysis, as reported at the 2025 American Diabetes Association (ADA), showed that 86% of such patients were taking two or more antidiabetic drugs and 41% of such patients were using insulin. After a 6-month treatment, a significant improvement of glycemic control was observed with HbA1c reduction from 8.1% to 7.3% with the mean time-in-range (TIR) levels increasing to over 70%. Thus far, the studies have demonstrated that when dorzagliatin is administered in combination with other antidiabetic drugs, such patients have experienced significantly improved post-meal glucose levels and improved β-cell function.Separately, a mechanistic study with dorzagliatin (employing double-tracer measurement) was conducted in the United States to provide scientific evidence of hepatic glycogen formation in T2D patients with an average of 17 years of diagnosed diabetes. In this study, patients were treated with dorzagliatin twice daily for 6 weeks. The results showed that dorzagliatin increased direct glucose flux to hepatic glycogen implying the improvement of restoration of hepatic Glucokinase (GK) function. Together with the clinical research data that dorzagliatin improves early phase insulin release and GLP-1 secretion, recovery of hepatic glycogen synthesis in T2D patients offers an important path in controlling post-meal glucose excursion and provides a unique opportunity in controlling diabetes complications, such as diabetes kidney diseases and mild cognition impairment.The RWE sponsored by Hua Medicine (HMM0601) has completed clinical trials with over 2,000 subjects, with average diabetes duration of 7.9 years and above 30% having disease duration more than 10 years. The initial results suggest that dorzagliatin is safe and well tolerated in Chinese T2DM patients. There were no new adverse effects observed in the study and the incident rate remains as low as what was observed in Phase III clinical trials. Patient adherence was generally high, with a mean adherence rate of approximately 95%. In this study, 80% of the participants have used one or more oral anti-diabetes medicine, and 20% used insulin. Dorzagliatin demonstrated good efficacy and safety not only in the overall population but also in elderly, obese, and hyperglycemic patient populations, whether used as monotherapy or in combination with metformin, SGLT2 inhibitors, insulin, and other medications. The topline results will be reported at the 2026 American Diabetes Association.- Deepened Clinical R&D, Continuous Expansion of New IndicationsNew Indication for Dorzagliatin – MODY-2 Patients.Medical experts in mainland China and Hong Kong have conducted independent clinical and preclinical studies of dorzagliatin for MODY-2 treatment. MODY-2, also called GCK-MODY, is a monogenic disease in which patients have a genetic defect of glucokinase gene (GCK) which results in elevated blood glucose and significant reduction of the second phase insulin secretion. The population of GCK-MODY patients is approximately 1.7 million in China. These patients are diagnosed with diabetes at a young age and represent an unmet medical need given that currently available medications are not effective. In clinical studies with MODY-2 patients, China investigators have reported that dorzagliatin is effective in reducing blood glucose levels to normal levels in MODY-2 patients who previously failed to manage their elevated blood glucose levels when treated with metformin, TZD, DPP-IV inhibitors, and SGLT-2 inhibitors. Additional results demonstrated that a single dose of dorzagliatin improved overall glucose sensitivity and second phase insulin secretion significantly in GCK-MODY patients, suggesting a unique mechanism of action of dorzagliatin to regulate GLP-1 secretion. Based on such results, Hua Medicine has communicated and reached a consensus with the CDE at NMPA to file the IND submission of dorzagliatin for MODY-2 patients in 2026.Dorzagliatin for Diabetes Prevention.Prevention of diabetes is an important focus at Hua Medicine. There are approximately 1.12 billion people living with prediabetes worldwide. We have initiated SENSITIZE 3 clinical study in Hong Kong in pre-diabetic (IGT) subjects and in early diabetes patients. These studies represent first-in-disease studies. In this double-blinded placebo-controlled study, we will evaluate the blood glucose management and pancreatic function under IVGTT and OGTT conditions to better define the clinical treatment baseline and endpoints. We expect to complete this study in 2026 and explore the opportunity to file IND applications of dorzagliatin for diabetes prevention in China and Asian Pacific regions thereafter. Dorzagliatin for Neurodegenerative Diseases.MCI shows approximately 15.5% prevalence among elderly people in China and approximately 22% in the US, and is common in T2D patients with a 45% incidence rate. The development of dorzagliatin for neurodegenerative disease is a new focus in our drug discovery efforts. Through the Genome-Wide Association Study (GWAS) and Mendelian Randomization (MR) study, we have realized the important role of GCK gene activation in the prevention of memory loss and cognitive impairment in humans. It has also come to our attention that post-meal glucose excursion is closely related to Alzheimer disease and dementia. The bio-energy balance in the brain is largely dependent on the glucose homeostasis control in the peripheral organ and the neural network communication in the central and peripheral system via spatial temporal management. Impaired glucose homeostasis and diabetes conditions result in a reduction of glucose transporter expression and insulin receptor expression in the brain, which can be prevented by low dose dorzagliatin. We have realized the potential of dorzagliatin in the treatment of mild cognitive impairment (MCI) and will initiate these first-in-disease clinical studies in the future.Dorzagliatin for Frailty.Frailty is an age-related geriatric syndrome characterized by reduced tolerance to internal and external stressors. Approximately 17% of Americans and 11% of Asians over the age of 50 suffer from frailty, while pre-frailty affects roughly 50% and 47% of these populations, respectively. It is not a single-organ disease, but the consequence of dysregulated multisystem homeostasis. Genetic evidence supports the causal effects of glucokinase (GK) activation on lowering frailty risk. We plan to initiate clinical studies in the future to advance dorzagliatin’s application in frailty.Development of combination therapy for diabetes and complications.Dorzagliatin rescues pancreatic function in glucose insulin secretion and GLP-1 secretion, as evidenced by clinical and basic research results. It also improves hepatic insulin sensitivity and reduces hepatic insulin resistance through recovery of hepatic glycogen synthesis in T2D patients. The combination of dorzagliatin with DPP-IV inhibitors, SGLT-2 inhibitors, and GLP-1 agonists have demonstrated effective regulation of lipid metabolism. Studies in combination with anticancer PI3K inhibitors have also offered unique benefits for glucose homeostasis management.- Diversified Product Pipeline, Innovative Layout for Future GrowthHua Medicine continues to enrich its pipeline layout based on core products. The Company has accelerated the R&D of a fixed-dose combination (FDC) of dorzagliatin and metformin as a twice-daily therapy for Type 2 diabetes patients with inadequate glycemic control on metformin alone, to further improve patient medication compliance. The product is supported by the strong results of the loose-dose combination in both Phase III clinical trials and real-world use. The Company has submitted an IND application to NMPA, and the GMP commercial manufacturing process has been successfully carried out, preparing for the pivotal bioequivalence study for NDA filing in 2027. Clinical studies have shown that the combination of dorzagliatin and metformin can better control blood glucose, reduce postprandial blood glucose and improve fasting blood glucose, providing new clinical value for optimizing blood glucose homeostasis endpoints.We have advanced our 2nd generation GKA as a once daily therapy for patients with obesity, leveraging dorzagliatin effects in improved glucose-stimulated GLP-1 secretion in the pancreas and in the intestine. The MAD study of the 2nd generation GKA was initiated in the United States with first-patient-in in December 2025, and we expect to report topline data by the middle of 2026.Meanwhile, the Company is also exploring combination therapy regimens of dorzagliatin with GLP-1 receptor agonists, SGLT-2 inhibitors and other drugs. In a recently published clinical trial in China, researchers reported the superior benefits of our dorzagliatin in combination with semaglutide as compared to semaglutide alone in a 12-week study. The combination group showed superior results across several key measures, including glycemic control, bodyweight related indicators and β-cell function.Financial Summary- Revenue generated by the Company was approximately RMB 492.9 million from the sale of approximately 4.011 million packs of HuaTangNing, increases of approximately 93% and 91% respectively, as compared with the year ended December 31, 2024.- Gross profit generated by the Company for the year ended December 31, 2025, was approximately RMB280.4 million, representing an increase of approximately 125%, as compared with the year ended December 31, 2024, and gross margins rose to 56.9%.- Profit before tax increased by approximately 542% to approximately RMB1,106.4 million for the year ended December 31, 2025, as compared with the year ended December 31, 2024.- Bank balances and cash position was approximately RMB1,092.3 million as of December 31, 2025.- Expenditures incurred by the Company for the year ended December 31, 2025, were approximately RMB433.4 million.Forward-Looking StatementsThis document contains statements regarding Hua Medicine's and its products' future expectations, plans and prospects. Such forward-looking statements relate only to events or information as of the date on which the statements are made in this document and are subject to change in light of future developments. Except as required by law, the Company shall not be obligated to update or publicly revise any forward-looking statements or unforeseen events after the date of such statements, whether as a result of new information, future events or other circumstances. Please read this document carefully and understand that actual future performance or results of the Company may differ materially from expectations due to various risks, uncertainties or other statutory requirements.About Hua MedicineHua Medicine (The “Company”) is an innovative drug development and commercialization company based in Shanghai, China, with companies in the United States and Hong Kong. Hua Medicine focuses on developing novel therapies for patients with unmet medical needs worldwide. Based on global resources, Hua Medicine teams up with global high-calibre people to develop breakthrough technologies and products, which contribute to innovation in diabetes care. Hua Medicine's cornerstone product HuaTangNing (dorzagliatin tablets), targets the glucose sensor glucokinase, restores glucose sensitivity in T2D patients, and stabilizes imbalances in blood glucose levels in patients. HuaTangNing was approved by the National Medical Products Administration (NMPA) of China on September 30th, 2022. It can be used alone or in combination with metformin for adult T2D patients. For patients with chronic kidney disease (CKD), no dose adjustment is required. It is an oral hypoglycemic drug that can be used for patients with Type 2 diabetes with renal function impairment. In February 2026, dorzagliatin (Trade name: MYHOMSIS®,) was approved for marketing by the Pharmaceutical Services of the Department of Health of the Government of the Hong Kong Special Administrative Region of China.For more informationHua MedicineWebsite: www.huamedicine.comInvestorsEmail: ir@huamedicine.comMediaEmail: pr@huamedicine.com Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

- 华堂宁(R)全年销量超400万盒，同比增长91%，销售额达4.929亿元，同比增长93%，公司全面自主商业化运营成效卓著。- 实现创纪录盈利，税前盈利达11.064亿元；现金余额稳健，截至年末达 10.923亿元，为持续运营发展奠定坚实基础。- 毛利率提升至56.9%，销售开支占比从59.9%优化至33.6%，盈利能力显著增强。- 华堂宁(R)原价续约新版医保目录，2026-2027年维持2025年的价格不变，临床价值和创新价值再获认可。- 随着PTE获批，中国市场独占权获5年延期至2034年4月，商业确定性进一步提升。- 多格列艾汀（HYHOMSIS(R) ，華領片(R)）获得香港地区上市批准，加速其面向东南亚的全球扩张进程。- 发布多项真实世界证据，证实多格列艾汀治疗优势。- 持续拓展血糖稳态治疗潜力，启动多项全新的疾病首创新适应症研究，研究范围涵盖糖尿病预防、罕见病、轻度认知障碍及衰弱症领域。上海, 2026年3月27日 - (亚太商讯 via SeaPRwire.com) - 华领医药（"公司"，香港联交所股份代号：2552）宣布公司及其附属公司截至2025年12月31日止年度（"报告期"）经审核的综合业绩。报告期内，公司核心产品、全球首创抗糖尿病新药、葡萄糖激酶激活剂（GKA）华堂宁(R)（多格列艾汀片）实现全方位推进，公司自主商业化团队于运营首年即实现高效组建和运转，研发管线持续丰富，财务表现实现历史性突破，成功迈入盈利新阶段，为全球糖尿病治疗领域的创新发展注入强劲动力。华领医药创始人、CEO陈力博士表示："2025年是华领医药商业化运营中的意义非凡的一年。公司成功完成从研发驱动型组织向商业化驱动型组织的转型，具备了全球首创新药、血糖稳态调节剂华堂宁(R)的完全自主商业化运营能力。凭借强劲的市场执行力与产品竞争力，相较于2024年将商业化业务委托给营销合作伙伴的阶段，公司的销量与营收实现了近三位数的增长。与此同时，通过推动多格列艾汀在香港的注册工作，公司在全球市场拓展方面取得了关键性进展，我们将向覆盖7亿人口的东南亚地区进行市场布局。我们持续拓展血糖稳态调控技术的临床应用场景，积极布局早期阿尔茨海默病、衰弱症等新适应症领域。针对GCK-MODY及衰弱症开展的疾病首创新药研发工作，将为华领医药未来五年的创新发展划定全新方向。"业务亮点与运营进展- 商业化全面发力，盈利实现历史性突破2025年1月1日起，公司正式全面接管华堂宁(R)在中国的商业化工作，获得全部运营与战略主导权，公司成功搭建了专业的销售团队，覆盖全国10个销售区域，专注于产品营销、医学事务及商业运营。通过人工智能赋能的数字商业化平台，运营效率与销售生产力大幅提升，为公司商业化发展注入新活力。受益于国家医保药品目录的持续广泛覆盖，华堂宁(R)在二级和三级医院的处方量显著增长，患者可及性不断提高，通过3000多家医院、社区卫生中心、药房和线上渠道，惠及超过50万名患者。报告期内，产品销量达401.1万盒，同比增长91%；销售额达4.929 亿元，同比增长93%，在单价保持稳定的情况下，充分印证了市场需求的强劲增长和自主商业化团队的高效执行能力。盈利能力方面，2025年，公司毛利达到2.804亿元，同比增长125%，得益于生产规模扩大及制造工艺优化，公司毛利率从2024年的48.7% 提升至56.9%，增加8.2个百分点；销售开支仅增长1230万元至1.655亿元，占收入比例优化至33.6%，较2024年的59.9%大幅下降；商业化业务实现约1.149亿元盈利（按毛利扣除销售开支计算）。公司预期仍将持续扩充商业化团队规模，但商业化运营的盈利趋势也将持续增长。在2024年底终止与拜耳合作后，多格列艾汀销售额创历史新高，报告期内，公司税前盈利增加至人民币11.064亿。截至2025年末，现金结余约为人民币10.923亿元，稳健的现金情况为公司持续发展奠定了坚实基础。- 全球布局加速推进，核心权益得到强化公司全球化布局迈出关键步伐。2026年2月27日，多格列艾汀（香港地区商品名：MYHOMSIS(R)，華領片(R)）成功获得香港监管机构的上市批准，公司计划2026年中正式在香港市场推出该产品，并将进一步向亚洲地区拓展。此外，公司已于2025年向澳门药监局递交華領片(R)（MYHOMSIS(R)）的新药上市申请。公司在知识产权保护方面也再获进展。2026年2月，中国国家知识产权局批准多格列艾汀专利期限补偿（PTE）申请，核心专利保护期延长至2034年4月，新增5年市场独占权，为产品长期市场竞争提供有力保障。2025年，多格列艾汀获中国监管机构认定为国家级创新药及慢病有效治疗药物，国家医保局已确认，2026-2027年，华堂宁(R)的国家医保目录价格维持不变，公司将持续保障产品的市场竞争力和患者可及性，尤其在二级和三级医院，加速患者的用药普及。- 真实世界研究推进，临床价值获持续验证真实世界证据（RWE）研究持续佐证多格列艾汀在葡萄糖依赖性胰岛分泌功能改善中的关键作用，并显示其在糖尿病预防、缓解及延缓或预防糖尿病并发症方面的功效。HMM0701已完成入组，共招募380名2型糖尿病患者。2025年6月，在美国ADA年会上发表的中期分析结果显示，86%的患者同时服用两种或以上降血糖药物，41%的患者使用胰岛素。经6个月治疗后，血糖控制明显改善，糖化血红蛋白由8.1%降至7.3%，平均TIR（目标范围内时间）提升至70%以上。迄今为止的研究显示，多格列艾汀与其他降糖药物联合使用时，患者的餐后血糖水平和β细胞功能均显著改善。另外，在美国进行的多格列艾汀机制研究（采用双示踪剂测量法），为平均确诊糖尿病17年的2型糖尿病患者的肝糖原生成提供了科学证据。在该研究中，患者每日服用两次多格列艾汀，持续6周。结果显示，多格列艾汀能增加葡萄糖直接流入肝糖原的通量，意味着其有助于恢复肝脏GK功能。结合临床研究数据显示，多格列艾汀可改善早期胰岛素释放和GLP-1分泌，恢复2型糖尿病患者的肝脏GK功能，不仅为控制餐后血糖波动提供重要途径，并在控制糖尿病并发症（如糖尿病肾病变及轻度认知障碍）方面提供独特契机。HMM0601研究已经完成临床试验，共纳入2000名受试者，平均患病时间为7.9年，其中超过30%患病时间超过10年。初步结果显示，多格列艾汀在中国2型糖尿病患者中安全性、耐受性良好。研究中未观察到新的不良反应，不良反应发生率维持在III期临床试验中观察到的低水平，患者的用药依从性普遍较高，平均依从率约为95%。在本研究中，80%的受试者已使用一种或多种口服降血糖药，20%的受试者使用胰岛素。多格列艾汀不仅在整体患者群体中展现出良好的疗效及安全性，在老年、肥胖及高血糖患者群体中同样有效，无论作为单药治疗或与二甲双胍、SGLT-2抑制剂、胰岛素及其他药物联合使用。顶线结果将于2026年ADA年会上发表。- 临床研发持续深化，新适应症不断拓展多格列艾汀用于治疗MODY-2患者。中国内地及香港地区医学专家已独立开展多格列艾汀用于MODY-2治疗的临床研究及临床前研究。MODY-2（又称GCK-MODY）是一种单基因疾病，患者因葡萄糖激酶基因(GCK)存在遗传缺陷，导致血糖升高及第二时相胰岛素释放显著减少。在中国，MODY-2患者群体规模约为170万人。此类患者确诊糖尿病时年龄偏小，且由于现有治疗药物疗效不佳，这一患者群体存在未被满足的医疗需求。中国研究人员在针对MODY-2患者的临床研究中报告指出，对于先前使用二甲双胍、TZD、DPP-4抑制剂及SGLT-2抑制剂仍无法控制高血糖的MODY-2患者，多格列艾汀能有效将血糖降至正常水平。其他结果显示，单剂量多格列艾汀可显著改善这类患者的整体葡萄糖敏感性及第二时相胰岛素分泌，表明多格列艾汀具有调节GLP-1分泌的独特作用机制。基于以上结果，华领医药已与国家药品监督管理局（NMPA）药品审评中心沟通，将于2026年提交多格列艾汀用于MODY-2患者的IND申请。多格列艾汀用于糖尿病预防。糖尿病预防是华领医药的重要研发重点。公司已于香港启动针对糖尿病前期糖耐量异常（IGT）受试者及早期糖尿病患者的SENSITIZE 3临床研究。这项双盲安慰剂对照研究将评估受试者在静脉葡萄糖耐量试验及口服葡萄糖耐量试验下的血糖控制及胰岛功能，以更明确界定临床治疗基线及终点指标。我们预计于2026年完成研究后，将在中国及亚太地区探索提交多格列艾汀用于糖尿病预防的IND申请的新机遇。多格列艾汀用于神经退行性疾病。研究显示，中国老年人的轻度认知障碍患病率约为15.5%，美国则约为22%；该症状在2型糖尿病患者中也相当常见，发病率达45%。多格列艾汀用于神经退行性疾病的研究已成为公司药物研发工作的新焦点。通过全基因组关联分析(GWAS)及孟德尔随机化（MR）研究，我们发现GK基因激活在预防人类记忆力衰退及认知障碍方面具有重要作用。同时我们也发现，餐后血糖波动与阿兹海默症及失智症密切相关。血糖稳态异常及糖尿病状况会导致大脑葡萄糖转运蛋白及胰岛素受体表达减少，而低剂量多格列艾汀可预防该功能损伤。我们已确认多格列艾汀在治疗轻度认知障碍方面的潜在价值，并将于未来启动针对该疾病领域的首创疗法的相关临床研究。多格列艾汀用于治疗衰弱症。衰弱症是一种与年龄相关的老年综合症，其特征为对内外应激因子的耐受性降低。约17%的美国人及11%的亚洲人（50岁以上）患有衰弱症，而处于衰弱症前期者则分别约占此两个群组的50%及47%。衰弱症并非单一器官疾病，而是多系统内稳态失调所导致的后果。遗传学证据支持GK激活对降低衰弱症风险具有因果作用。我们计划于未来启动临床研究，以推进多格列艾汀在衰弱症治疗领域的应用。联合用药用于糖尿病及并发症的治疗。临床与基础研究结果显示，多格列艾汀能恢复胰腺在葡萄糖刺激下的胰岛素及GLP-1分泌，也可以通过恢复2型糖尿病患者肝脏葡萄糖激酶功能，改善肝脏胰岛素敏感性并降低肝脏胰岛素抵抗。多格列艾汀与DPP-4抑制剂、SGLT-2抑制剂及GLP-1受体激动剂的联合使用已证明可有效调节脂质代谢，与抗癌PI3K抑制剂联合使用的研究也为血糖稳态管理带来独特优势。- 产品管线丰富多元，创新布局未来增长华领医药在核心产品基础上持续丰富管线布局。依托多格列艾汀与二甲双胍联合用药在III期临床试验和真实世界应用中取得的优异数据，公司加速推进多格列艾汀与二甲双胍固定复方制剂（FDC）的研发。该制剂为每日两次给药方案，适用于单用二甲双胍血糖控制不佳的2型糖尿病患者，旨在以进一步提升患者的用药依从性。公司已向NMPA提交IND申请文件。此外，GMP商业化生产工艺也已成功开展，为2027年新药上市申请的关键生物等效性研究做好准备。临床研究显示，多格列艾汀与二甲双胍联用能够更好地控制血糖，降低餐后血糖，改善空腹血糖，为优化血糖稳态终点提供了新的临床价值。第二代GKA的研发取得重要突破。作为肥胖2型糖尿病患者每日一次治疗的缓释新片剂，公司已在美国启动多格列艾汀多剂量递增（MAD）研究，以探讨第二代GKA在血糖稳态控制方面的疗效及新药的作用机制，首例患者已于2025年12月入组，预计2026年中公布顶线数据。同时，公司还在探索多格列艾汀与GLP-1受体激动剂、SGLT-2抑制剂等药物的联合治疗方案。近期，在一项中国的临床试验中，研究者报告：多格列艾汀联合司美格鲁肽治疗12周，疗效显著优于司美格鲁肽单药治疗。联合治疗组在血糖控制、体重相关指标及β细胞功能等多项关键指标上均表现更优。财务摘要截至2025年12月31日，- 华堂宁(R)全年销量约401.1万盒，相较2024年全年，同比增长91%，实现营收约4.929亿元，同比增长93%。- 毛利约人民币2.804亿元，同比增长125%，毛利率提升至56.9%；- 税前盈利约人民币11.064亿元，较2024年增长542%；- 银行结余及现金约人民币10.923亿元，资金状况稳健；- 总开支约人民币4.334亿。前瞻性声明本文包含有关华领医药以及产品未来预期、计划和前景的陈述。该等前瞻性陈述仅与本文作出该陈述当日的事件或资料有关，可能因未来发展而出现变动。除法律规定外，于作出前瞻性陈述当日之后，无论是否出现新资料、未来事件或其他情况，我们并无责任更新或公开修改任何前瞻性陈述及预料之外的事件。请仔细阅读本文并理解，由于各种风险、不确定性或其他法定要求我们的实际未来业绩或表现可能与预期有重大差异。关于华领华领医药（"本公司"）是一家总部位于中国上海的创新药物研发和商业化公司，在美国、中国香港设立了公司。华领医药专注于未被满足的医疗需求，为全球患者开发全新疗法。华领医药汇聚全球医药行业高素质人才，融合全球创新技术，依托全球优势资源，研究开发突破性的技术和产品，引领全球糖尿病医疗创新。公司核心产品华堂宁(R)（多格列艾汀片）以葡萄糖传感器葡萄糖激酶为靶点，提升2型糖尿病患者的葡萄糖敏感性，改善患者血糖稳态失调。2022年9月30日，华堂宁(R)已获得中国国家药品监督管理局（NMPA）的上市批准，用于单独用药或者与二甲双胍联合用药，治疗成人2型糖尿病。对于肾功能不全患者，无需调整剂量，是一款可用于肾功能损伤的2型糖尿病患者的口服降糖药物。2026年2月，多格列艾汀（商品名：MYHOMSIS(R)，華領片(R)）获得中国香港特别行政区政府卫生署药物办公室的上市批准。详情垂询华领医药网址：www.huamedicine.com投资者电邮：ir@huamedicine.com媒体电邮：pr@huamedicine.com新闻免责声明本材料，如为上下文论述的准确性和完整性，提及在中国上市的产品相关信息的，特别是标识或要求，应遵循中国监管机构批准的相关文件。另外，相关信息不应被解读为对任何药物或者诊疗方案的推荐或者宣传，亦不应替代任何医疗卫生专业人士的医疗建议，涉及医疗的相关事宜务必咨询医疗卫生专业人士。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年3月27日 - (亚太商讯 via SeaPRwire.com) - 3月26日，云知声（09678.HK）发布截至2025年12月31日止年度的经审核全年业绩，展现上市后首份成绩单强劲的增长动能与持续优化的财务结构。营收结构持续优化，下半年增长提速2025年全年，云知声实现总营收12.1亿元人民币，同比增长29%。其中，下半年收入同比增长33%，达8.1亿元。值得关注的是，公司大模型业务全年收入6.1亿元，同比增长超10倍。尤其是下半年，该业务贡献收入约5亿元，为上半年规模的5倍，显示出强劲的规模化落地能力。亏损大幅收窄，盈利路径日渐清晰在营收高速增长的同时，公司亏损状况显著改善。2025年下半年，公司净亏损同比收窄84%，经调整后亏损同比收窄92%，接近盈亏平衡点，反映出公司在成本控制与运营效率方面的持续优化。同时，公司的部分经营指标也得到明显改善。经调整营业费用率较去年同比大幅下降10%，销售费用不升反降，占收入比重仅为5.4%，费效比提升明显。从数据端来看，2025年公司人均产值为252万元/人，相较24年的202万元同比增长25%，人均创效能力持续领跑行业，直观彰显了公司技术驱动、精益运营的核心优势。双轮驱动战略落地，智慧医疗与智慧生活齐头并进2025年，在技术突破与政策红利的双重驱动下，全球人工智能市场需求持续升温。云知声坚持「强基模+深应用」战略，持续夯实全模态技术底座，推动自研大模型矩阵在医疗、语音、OCR等领域的全球影响力不断提升。在商业化层面，公司以AI原生组织推动业务落地，智慧医疗与智慧生活双轮驱动战略成效显著。报告期内：智慧生活业务实现收入9.68亿元，同比增长30.8%。其中，智慧交通业务同比增长近40%，目前，已在青岛、宁波、深圳、南宁等10余个城市落地基于山海大模型的智能体应用。此外，AI芯片累计出货量突破1.1亿颗，进一步验证公司在终端AI产品的规模化能力。智慧医疗业务实现收入2.44亿元，同比增长22.3%，客单价同比增长53.2%。2025年，合作的医院中超70%为三级医院，且超过三分之一客户已经连续合作三年以上；而基于医疗大模型的病历录入与生成产品已在某头部三甲医院单院区实现全年病历生成同比增长10倍；商业保险智能体平台案件处理量同比增长37倍；与头部保险集团的深度合作中，控费率水平有效提升至约20%，相较传统审核方式实现超10亿元级别的增量成本管控，全面赋能保险机构在医疗风控领域的精细化运营。持续加码研发，夯实技术护城河为巩固行业领先地位，2025年公司持续在技术端大力投入，全年研发费用超3.8亿元，占经调整三费的75%；研发人员占比达69%。持续的研发投入在多个技术领域取得突破，如在MedBench 4.0评测中，公司一举斩获"医疗智能体""医疗大语言模型""医疗多模态大模型"三项技术范式第一，荣膺"三冠王"。未来展望：深耕技术底座，拓展应用边界展望未来，云知声将继续深化"强基模+深应用"战略。技术层面，公司将持续加大对基座大模型的战略性投入，力争保持全球一流水平；应用层面，将以MaaS（模型即服务）与智能体的规模化拓展为核心增长引擎，推动智慧生活与智慧医疗业务的指数级增长。同时，公司正积极探索以API调用、Token计费等模式构建经常性收入体系，并将C端产品机会作为第二增长曲线，进一步拓展商业化边界。2026年第二季度，云知声将推出面向编程和办公的原生智能体大模型，并预计能实现智能密度和Token生产效率的倍增。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Mar 27, 2026 - (ACN Newswire via SeaPRwire.com) – 26 March, Unisound (09678.HK) announced its audited annual results for the year ended December 31, 2025. As the Company's first annual results announcement since listing, it underscores strong growth momentum and continued improvement in its financial profile.Revenue Mix Continues to Improve, with Faster Growth in H2For the full year of 2025, Unisound achieved total revenue of $175 million, representing a year-on-year (YoY) increase of 29%. Revenue in the second half of the year increased by 33% YoY to $117 million.It is worth noting that the Company's large language model (LLM) business generated a full-year revenue of $88.43 million, surging by over 10 times YoY. In particular, this business contributed approximately $72.49 million in H2 revenue, five times the level recorded in H1, demonstrating a compelling capacity for large-scale commercial application.Losses Narrowed Significantly, Making the Path to Profitability Increasingly ClearAlongside the rapid revenue growth, the Company's losses improved markedly. In the second half of 2025, the Company's net loss narrowed by 84% YoY, and its adjusted loss narrowed by 92% YoY, approaching break-even. This reflects the Company's ongoing improvements in cost control and operational efficiency.Simultaneously, some of the Company's operating metrics saw marked improvement. The adjusted expense ratio declined significantly by 10 percentage points YoY, while selling expenses decreased rather than increased and accounted for only 5.4%, highlighting a clear improvement in cost-to-efficiency ratio. In 2025, revenue per employee reached $365,300, up 25% YoY from $292,900 in 2024. Employee productivity continued to lead the industry, clearly underscoring the Company's core strengths in technology-driven, lean operations.Dual-Engine Strategy Gains Traction, with AI in Healthcare and AI in Daily Life Advancing in TandemIn 2025, driven by both technological breakthroughs and policy tailwinds, global demand for AI continued to rise. Unisound adhered to its "Strong Foundation Model + Deep Application" strategy, continued to strengthen its multimodal technology foundation, and drove the continuous elevation of the global influence of its proprietary large model matrix in fields such as healthcare, speech, and OCR.On the commercialization front, the Company leveraged its AI-native organization to accelerate business execution, and its dual-engine strategy in AI in Healthcare and AI in Daily Life delivered notable results. During the reporting period:The AI in Daily Life business achieved revenue of $140 million, a YoY increase of 30.8%. Among this, the Transportation segment recorded nearly 40% YoY growth. At present, AI agent applications based on the Shanhai large model have been deployed in more than 10 cities, including Qingdao, Ningbo, Shenzhen and Nanning. In addition, cumulative AI chip shipments exceeded 110 million units, further validating the Company's scale capabilities in endpoint AI products.The AI in Healthcare business achieved revenue of $35.38 million, a YoY increase of 22.3%, with average revenue per customer growing by 53.2% YoY. In 2025, over 70% of the hospitals the Company collaborated with were tertiary hospitals, and more than one-third of customers had maintained continuous cooperation for over three years. The medical-record entry and generation products powered by the medical large model delivered a 10-fold YoY increase in full-annual medical record generation at a single campus of a leading Class III hospital. The commercial insurance AI agent platform recorded a 37-fold YoY increase in case processing volume. In deep cooperation with a leading insurance group, the expense control rate was effectively raised to approximately 20%, delivering more than $145 million in incremental cost management compared with traditional review methods, comprehensively empowering insurance institutions to refine their medical risk management operations.Continued R&D Investment Strengthens the Technology MoatTo consolidate its industry-leading position, the Company continued to invest heavily in R&D in 2025. Full-year R&D expenses exceeded $55.09 million, accounting for 75% of the Company's adjusted operating expenses, while R&D personnel accounted for 69% of the total workforce. This sustained investment drove breakthroughs across multiple technology areas. For example, in the MedBench 4.0 evaluation, the Company ranked first place in three technical paradigms: "Medical AI Agent," "Medical Large Language Model," and "Medical Multimodal Large Model," earning a "Triple Crown."Outlook: Deepening the Technological Foundation and Expanding Application BoundariesLooking ahead, Unisound will continue to deepen its "Strong Foundation Model + Deep Application" strategy. On the technological front, the Company will continue to increase strategic investment in foundational large models and strive to maintain a world-class level. On the application front, it will use the large-scale expansion of MaaS (Model-as-a-Service) and AI agents as its core growth engine, driving exponential growth in its AI in Daily Life and AI in Healthcare businesses. Meanwhile, the Company is actively exploring the establishment of a recurring revenue system through models such as API calls and Token-based billing, and regards opportunities in consumer-facing (C-end) products as a second growth curve to further expand its commercialization boundaries.Between Q2 and Q3 2026, Unisound will launch a native AI agent large model for programming and office applications, which is expected to double both intelligence density and token production efficiency. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年3月27日 - (亚太商讯 via SeaPRwire.com) - 2026年3月26日，北京城建设计发展集团股份有限公司（"本公司"或"公司"，简称"城建设计"，股票代码：1599.HK）董事会（"董事会"）欣然公布本公司及其子公司（合称"本集团"）截至2025年12月31日止年度（"2025年度"或"报告期"）的经审计业绩。2025年，公司面对市场持续下行压力，紧紧围绕高质量发展，迎难而上、实干担当，聚焦主责主业，推动全产业链协同发力，阶段性完成了"十四五"规划主要目标任务，为新征程加快发展积蓄了强劲动能。截至2025年12月31日止年度，本集团实现收入为人民币75.27亿元。本集团实现净利润为人民币5.36亿元，同比上涨1.52%。综合毛利率19.85%，同比上涨1.77%。核心主业与新兴领域协同发力，高端咨询品牌效应显现设计、勘察及咨询板块为本集团的传统和主营核心业务，报告期内，本集团轨道交通领域中标成都27号线二期、厦漳泉城际铁路（厦门段）等重点项目；既有线改造市场成效显著，中标北京、南京、哈尔滨、长春、沈阳等一批代表性项目，市场份额保持领先；高端咨询品牌效应持续显现，成功承担了香港铁路标准、北京三期线网技术标准等标杆项目，专业服务能力稳步提升；境外业务扎实推进，在香港、新加坡、安哥拉、哈萨克斯坦、哥伦比亚持续获取订 单，新签合同额突破人民币1亿元；民建、市政设计走特色化发展之路，在居住建筑、大型TOD、校园、道路等传统领域精耕细作，积极向展陈、城市更新、水环境治理领域延伸布局。截至2025年12月31日止年度，本集团设计、勘察及咨询板块业务收入人民币40.89亿元。其中城市轨道交通工程板块收入人民币29.38亿元，工业与民用建筑和市政工程板块收入人民币11.51亿元。本集团工程承包业务板块专注于服务城市轨道交通建设项目和相关基础设施建设项目，2025年，本集团中标北京轨道交通R4线一期北段01标、03标、M101线05标、市郊铁路东北环线03标等项目，进一步巩固了北京核心市场，在手工程承包项目主要集中在北京、广州、重庆、乌鲁木齐及青岛等城市。截至2025年12月31日止年度，本集团工程承包业务板块实现收入人民币34.38亿元。新建项目与存量改造双线发力，中标额突破81亿元，在手订单储备充足2025年，轨道交通行业面临市场持续下行、招标规模显著缩减、行业竞争加剧及宏观经济形势不确定性增强的局面，公司始终全力以赴力争中标轨道交通新建项目，尤其注重稳固北京区域市场份额。在守住基本盘的同时，积极布局既有线改造、城市更新、能源、数字化及智慧等其他高潜力板块，以应对市场变化并提升抗风险能力。截至2025年12月31日，公司中标金额人民币81.71亿元，其中设计、勘察及咨询业务板块中标人民币26.39亿元，工程总承包板块中标人民币55.32亿元。报告期末公司在手合同额为人民币251.43亿元。2026年展望：锚定"十五五"开局，推动高质量发展2026年是"十五五"开局之年，面对深刻变化的市场形势和艰巨繁重的发展任务，我们要积极把握战略机遇，主动适应行业发展新格局，以稳中求进为总基调，以推动高质量发展为主题，以改革创新为根本动力，锚定打造"以设计为引领的城市建设综合服务商"战略目标，确保"十五五"开好局、起好步。有关城建设计北京城建设计发展集团股份有限公司（股份代码：1599.HK）是国内第一家以城市轨道交通设计咨询为引领的H股上市企业。公司前身是北京城建设计研究总院成立于1958年，是为中国首条地铁北京地铁1号线的勘察设计而成立。拥有国内设计勘察行业最高资质—综合甲级资质。作为行业龙头和市场规范的制定者，公司由成立至今仍保持市场占有率第一的位置。基本业务涵盖投融资、勘察设计咨询、工程总承包、科技产业化、运营管理的城市轨道交通全产业链。公司市场覆盖了全国已批复轨道交通建设规划城市的80%，业务拓展到了国内近70个城市，在50多个城市拥有分支机构。新闻垂询：千里国际顾问有限公司fancywang@maxima.hk Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年3月27日 - (亚太商讯 via SeaPRwire.com) - 2026年3月26日，心玮医疗（06609.HK）公布了2025年业绩公告。2025度，公司收入4.08亿元，同比增长46.9%，净利润8334万元，较上年度亏损约1362万元实现重大扭亏为盈。这一转变主要由于公司在缺血性卒中、出血性卒中及介入通路三大业务板块均实现了收入的快速增长，同时公司的经营效率进一步提升。2025年，公司的缺血性卒中业务收入同比增长31.8%，主要由于：(1)公司具有差异化竞争优势的颅内血栓抽吸导管得到临床的广泛认可，大腔抽吸及级联抽吸技术(CATCH)被纳入《急性缺血性卒中血管内治疗技术中国专家共识2025》，产品进入超过450家医院使用，收入规模快速提升；(2)成熟产品在纳入集采后，销量快速增长。在出血性脑卒业务中，公司已构建完整动脉瘤治疗解决方案。公司的颅内支架（获NMPA创新医疗器械认定）在首个商业化年度累计进入约500家医院使用，带动栓塞弹簧圈的市场份额快速提升。同时，公司的血流导向装置于2025年获NMPA批准上市，实现临床推广和应用。基于前述原因，公司的出血性卒中业务收入在2025年同比增长223.2%。在介入通路业务中，公司的明星产品血管封堵器累计进入超过1800家医院使用，年终端医院临床使用量超过20万条，在2025年实现单产品收入过亿。与此同时，公司正推动第二代血管封堵器的开发和商业化，以继续扩大市场份额。公司的毛利率从2024年度的65.4%提升至2025年的70.9%，主要由于高毛利创新产品的收入占比提升，以及公司持续推动的生产工艺改进、供应链优化等降本措施的有效实施。不断完善的产品布局以及持续的降本增效工作，使公司在面临激烈的市场竞争情况下，仍能保持优质的产品质量及突出盈利能力。公司在业务规模扩大的同时，费用控制效果显著，销售及管理费用率较2024年相比从49.6%降至45.8%。报告期内，公司发生研发费用人民币4076万元，主要用于神经介入医疗器械及脑机接口等创新产品的开发。截至目前，公司已取得以下各项进展：(1)在缺血性卒中领域，公司已取得颅内血栓抽吸导管、取栓支架及配套通路产品的注册证。公司的自膨式颅内药物洗脱支架已完成对照临床试验，注册申请已获NMPA受理。根据公开信息查询结果，目前全球未有类似产品获批上市，公司在此类产品的研发进度上领先业界。在颈动脉狭窄领域，公司正推动开展颈动脉支架的临床试验工作；(2)在出血性卒中领域，公司是获证最全面的国产公司，实现颅内支架（获NMPA创新医疗器械认定）、血流导向装置、栓塞弹簧圈、神经血管封堵球囊导管的完整布局；(3)同时，公司正积极推进创新产品介入式脑机接口的研发工作。该产品在有效提取大脑信号以用于完成人机交互的同时，保障了手术的安全性和产品长期植入的稳定性，有望在2026年开展首例人体临床试验。2025年，公司的海外市场收入较2024年增长101.3%，这主要归功于公司快速推进的海外产品注册工作及产品推广工作。海外市场方面，公司的取栓支架、封堵球囊导管、远端通路导管以及微导管已取得CE或FDA认证，并在其他13个国家或地区取得56项注册证书。截至目前，公司还在其他29个国家或地区开展超过130个产品注册工作，扩展销售管道，为实现海外销售的长期目标建立基础。2025年，公司经营性现金流1.55亿元，账面现金及存款7.86亿元，整体资金状况稳健。依托扎实的财务实力，公司已于2025年完成股份回购3936万港元，并将持续推进股份回购工作，积极维护全体股东利益。此外，公司计划于2026年提交A股科创板上市申请，借助登陆境内资本市场进一步提升股东回报水平与股份市场流动性。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

财务摘要人民币（亿元）截至12月31日止12个月变动2025年2024年营业收入1566.111,776.64-11.85%营业利润28.4265.53-56.64%税前利润28.1665.95-57.30%毛利194.95222.47-12.37%毛利率12.45%12.52%-0.07pct净利润13.3741.95-68.12%归属于母公司股东及其他权益持有者的净利润2.2129.72-92.57%经营活动产生的现金流量净额185.1492.6499.86%每股派息（元/股，含税）0.1790.176N/A派发现金红利（含税）9.399.45-0.60%业绩亮点1.经营底盘稳健，高质量发展韧性凸显：2025年集团实现营业收入人民币1566.11亿元，净利润人民币13.37亿元，毛利率维持12.45%，海内外营收结构均衡。2.现金流与财务质量双改善，抗风险能力显著增强：经营活动现金流净额大幅增长99.86%至185.14亿元，期末货币资金余额243亿元；有息债务规模同比缩减47亿元至人民币344亿元、净利息费用同比下降约7.3亿元，财务结构持续优化。3.现金分红+回购双管齐下，全力回报投资者：2025年拟每股派现金人民币0.179元(含税)，叠加年内推出的H股、A股多轮回购计划，2025年度公司拟分红及已回购金额合计达到人民币18.52亿元。4.能源相关业务盈利能力大幅跃升，成为集团重要增长极：海洋工程分部、金融资产管理分部(主要为钻井租赁)净利润合计增长约12.12亿，能源化工及液态食品分部增长3.08亿。其中，海洋工程分部毛利率大幅提升5.72个百分点至14.83%。海洋工程、能源化工及液态食品在手订单分别达50.9亿美金及297.5亿人民币，部分船厂排产至2030年。5.物流相关业务稳固集团"压舱石"作用：期内，集装箱、道路运输车辆等业务受汇率及周期波动影响，毛利率及盈利有所承压，但基本盘稳健，行业竞争优势持续巩固，集装箱标准干箱、冷藏箱、化工罐箱、半挂车等核心产品连续多年保持全球第一。6.关键业务取得技术与订单双突破，竞争力获高度认可：高端海工装备领域，中集来福士攻克海工行业最复杂产品FPSO/FLNG，成为中国唯一一家拥有双项目EPCI总包能力的企业；模块化数据中心领域，同时为超过300MW的行业客户提供预制化数据中心的技术与制造交付服务，引领算力基础设施新变革。香港, 2026年3月26日 - (亚太商讯 via SeaPRwire.com) - 中国国际海运集装箱（集团）股份有限公司（简称"中集集团"或"集团"，股份代号：000039.SZ/02039.HK）欣然公布截至2025年12月31日止12个月（"期内"）之经审核全年业绩。中集集团管理层表示，2025年，全球百年变局加速演进，世界经济在波折中展现韧性。置身于机遇与挑战并存的时代洪流，集团紧紧围绕"构建增长新动能、聚力高质量发展"主基调，不仅稳住经营基本盘，更以前瞻性战略深化能源业务布局，取得丰硕成果。2025年全年，集团实现营业收入人民币1566.1亿元，净利润达人民币13.4亿，公司经营活动产生的现金流量净额大幅增长99.9%至185.1亿元，资产结构持续优化，抗风险能力持续增强。特别地，为真情回馈广大投资者，中集集团2025年拟向全体股东每1股分派现金股利人民币0.179元（含税），此次合计拟派发现金红利人民币9.39亿元（含税）；同时，中集集团于2025年度已实施的股份回购金额累计达9.13亿人民币，两者合计总额达到18.52亿元。 主要板块经营表现（人民币亿元）2025各项指标营业收入占总营收比重毛利占总毛利比重毛利率净利润集装箱制造430.0927.46%57.5529.52%13.38%18.82道路运输车辆201.7812.88%32.0616.45%15.89%9.27能源、化工液态食品装备271.9217.36%40.2420.64%14.80%10.40海洋工程179.3811.45%26.6013.65%14.83%10.57物流服务267.9317.11%16.708.57%6.23%3.64空港与物流装备、消防与救援设备76.194.86%15.147.76%19.87%2.64以上主要板块1427.2991.12%188.2996.59%13.19%55.34核心业务表现一、在物流领域集装箱制造方面: 期内，虽受美国关税政策扰动与地缘政治冲突等供应链负面因素影响，全球商品贸易仍展现出较强韧性，区域内贸易、亚欧及新兴市场航线成为增量主力。与此同时，红海绕行、港口拥堵、航运环保要求及贸易路径复杂化等因素，降低了集运效率，从底层推升实际需求，全球集装箱保有量进入新的结构性阶段。综上，2025年集装箱新箱整体需求仍保持较好水平，高于过去十年均值。报告期内，集团集装箱制造业务产销量同比有所回落，符合行业整体预期，但仍旧保持全球第一。其中干货集装箱累计销量222.49万TEU（去年同期：343.36万TEU），同比下降35.2%；冷藏箱累计销量20.82万TEU（去年同期：13.86万TEU），同比增长50.2%。期内，集装箱板块实现营业收入430.09亿元，净利润18.82亿元，毛利率略有下降至13.38%。物流服务业务方面: 期内，该业务实现营业收入人民币267.93亿元，同比下降14.64%；净利润为人民币3.64亿元，同比下降16.65%，符合行业趋势变化。中集世联达主动调整业务架构，整合业务资源，期内海运业务自揽货量同比增长6%，港口物流业务的二手箱交易、仓储分拨创历史新高，行业物流业务聚焦新能源、汽车、工程项目等重点领域巩固细分优势。2025年，中集世联达在中国国际货运代理协会发布的"货代物流企业综合榜"中连续3年位列前五。道路运输车辆方面: 期内，中集车辆实现收入人民币201.78亿元，同比下降3.91%；实现净利润人民币9.27亿元，同比下降14.29%。国内市场方面，"星链计划"重塑组织运营模式，中国半挂车业务营业收入同比增长14.65%，毛利率同比提升3.3%。海外市场方面，全球南方市场业务延续高质量增长，期内营收规模达30.9亿元，同比增长17.7%，销量同比大幅提升29.1%，毛利率同比提升1.3个百分点。DTB业务销量和营收稳健增长,上装产品总计28,570台，整体收入达人民币31.84亿元，同比增长4.97%，核心产品市场占有率进一步提升。同时，持续积极扩展新能源产品的研与销力度，全面构建EV-RT生态圈，深度推进纯电动头挂列车的战略发展。空港与物流装备、消防与救援设备方面: 得益于优质订单释放结转，期内实现营业收入人民币76.19亿元，同比增长5.92%；实现净利润人民币2.64亿元。空港装备成功交付西安咸阳国际机场、土耳其安塔利亚机场及兰州机场等智能登机桥项目，亦凭借自主研发的创新装配式固定桥，中标南宁机场二期、杭州机场T2/T4连廊两大重点项目；物流装备交付国内化工行业石化炼化项目一体化项目配套自动化立体仓库；消防与救援设备业务推动国产制造海外突围，同时重点布局智慧消防与无人消防车前沿领域。二、在能源领域能源、化工及液态食品装备业务方面，实现营业收入人民币271.92亿元，同比上升6.31%；净利润大幅增长42.15%至人民币10.40亿元。其中，中集安瑞科实现营业收入人民币263.26亿元，同比增长6.3%。具体来看，清洁能源分部水上与陆上业务同步发力，在高压、低温等关键装备的市场持续获得领先份额，同时精准抓住天然气在水陆交通、发电等领域的应用增长机遇，同时积极开拓特种工业气体设备在高新科技产业的新兴增长空间。2025年，该分部新签订单达222.29亿元，创历史新高，其中水上清洁能源相关业务截至2025年底在手订单超人民币190亿元，造船业务已排产至2028年。报告期内成功投产第二个焦炉气综合利用项目--凌钢一期项目、建成国内首个量产生物甲醇项目并实现投产；化工环境分部市场份额稳居首位，医疗设备部件业务、后市场服务业务保持稳健增长。截至2025年年末的在手订单同比增长36.27%至12.76亿元，为后期发展提供较好保障；液态食品分部盈利能力稳健，毛利率较同期提升至21.7%。海洋工程方面，主要经营主体中集来福士成功实现从"建造主导"向"设计+建造+集成"一体化服务的战略转型，国内市场稳居领先，跻身国际海工市场重要新生力量。报告期内实现营业收入人民币179.38亿元，同比增长8.35%；净盈利人民币10.57亿元，成集团第二大盈利板块。得益于全球海工市场复苏，以FPSO/FLNG为代表的高端油气装备需求强劲，同时全行业正加速向绿色化与智能化转型，新能源装备订单保持稳定增长。年内，公司新签合同订单12.0亿美元，包括12+8条集装箱支线船、2条海工特种船及其它模块订单。截止2025年底，海洋工程板块累计持有在手订单价值50.9亿美元，其中油气、特种船订单占比约为7:3，其中龙口基地已排产至2030年。海工资产运营管理业务方面，公司持续发挥现有项目经验和业务能力，借助优异的海工平台运营管理能力，提高资产上租率。报告期内，第六代半潜钻井平台"仙境烟台"完成续租签约；超深水半潜钻井平台"蓝鲸一号"与国际客户签署新租约；半潜式起重/生活平台"Blue Gretha（原华电中集01）"与国际客户签署新租约；其他多座平台也在通过多种渠道积极参与市场招标，寻求资产处置及租赁等业务机会。报告期内，上租半潜钻井平台及自升式钻井平台的平均日费率均实现同比增长。未来发展和展望集团管理层表示："2026年是'十五五'规划开局之年，集团将以全新升级的品牌标志为起点，紧紧围绕'固本强基、开拓创新、提质增效'，以更加积极主动的战略姿态，在复杂变局中育新机、开新局，努力建设'高质量的、受人尊敬的世界一流企业'。"关于中国国际海运集装箱（集团）股份有限公司中集集团是全球领先的物流及能源行业设备及解决方案供货商，产业集群主要涵盖物流领域及能源行业领域，龙头市场地位持续巩固。在物流领域，本集团仍然坚持以集装箱制造业务为核心，孵化出道路运输车辆业务、空港与物流装备/消防与救援设备业务，辅之以物流服务业务及循环载具业务提供物流专业领域的产品及服务；在能源行业领域，本集团主要从能源/化工/液态食品装备业务、海洋工程业务方面开展；同时，本集团也在不断开发新兴产业并拥有服务本集团自身的金融及资产管理业务。作为一家为全球市场服务的多元化跨国产业集团，中集在亚洲、北美、欧洲、澳洲等地区拥有300余家成员企业，共拥有4家上市公司，客户和销售网络分布在全球100多个国家和地区。2025年，本集团业绩实现营业收入人民币1566亿元，位列2025《财富》中国500强榜单第154名。在集装箱标准干箱、冷藏箱、化工罐箱、半挂车等核心产品领域连续多年保持全球第一。如欲获得更多信息，请浏览https://www.cimc.com/。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Financial HighlightsRMB 100 millionFor the 12 months ended 31 DecemberChange (%)20252024Revenue1566.111,776.64-11.85% Profit28.4265.53-56.64% Profit before Tax28.1665.95-57.30% Gross Profit194.95222.47-12.37% Gross Profit Margin12.45%12.52%-0.07pct Net Profit13.3741.95-68.12% Net Profit Attributable to Shareholders and Other Equity Holders2.2129.72-92.57% Net cash flows from operating activities 185.1492.6499.86% Dividend per share (RMB/share, tax inclusive)RMB 0.179RMB 0.176N/A Total dividend payout9.399.45-0.60% Performance Highlights1. Solid operating core segments with resilient high-quality development: In 2025, the Group achieved revenue of RMB 156.611 billion, net profit of RMB 1.337 billion, and maintained a gross profit margin of 12.45%, with a balanced domestic and overseas revenue structure.2. Dual improvement in cash flow and financial quality, with significantly enhanced risk resilience: Net cash flows from operating activities increased substantially by 99.86% to RMB 18.514 billion, while the cash and cash equivalents as of the end of the Year reached RMB 24.3 billion; the scale of interest-bearing debt decreased by RMB 4.7 billion year-on-year (“YoY”) to RMB 34.4 billion, and net interest expenses decreased by approximately RMB 730 million YoY, with the financial structure continuing to be optimized.3. Cash dividends and share buybacks implemented in parallel to reward investors: The Group proposes a cash dividend of RMB 0.179 per share (tax inclusive) for 2025. Together with multiple rounds of H-share and A-share buyback plans launched during the Year, the total proposed dividend and completed buybacks for 2025 amounted to RMB 1.852 billion.4. Significant improvement in profitability of energy-related businesses, becoming a key growth driver of the Group: Net profit of the offshore engineering segment and the financial and asset management segment (primarily drilling platform leasing) increased by approximately RMB 1.212 billion in total, while the energy, chemical and liquid food equipment segment increased by RMB 308 million. Among them, the gross profit margin of the offshore engineering segment increased significantly by 5.72 percentage points to 14.83%. Orders on hand for offshore engineering and energy, chemical and liquid food equipment reached US$5.09 billion and RMB 29.75 billion, respectively, with certain shipyards’ production schedules extending to 2030.5. Logistics-related businesses continued to serve as the Group’s “ballast stone”: During the Year, businesses such as container manufacturing and road transportation vehicles were affected by exchange rate fluctuations and cyclical changes, resulting in pressure on gross profit margins and profitability. However, the core segments remained solid, and the Group’s competitive advantages in the industry continued to be consolidated. Core products such as standard dry containers, reefer containers, tank containers and semi-trailers have maintained the world’s No.1 position for many consecutive years.6. Breakthroughs in both technology and orders in key businesses, with competitiveness highly recognised: In the high-end offshore engineering equipment sector, CIMC Raffles successfully developed the most complex products in the offshore industry, including FPSO/FLNG, becoming the only enterprise in China with dual-project EPCI general contracting capabilities; in the modular data center sector, the Group providing technical and manufacturing delivery services of prefabrication data center to industry customers exceeding 300MW, leading new transformation in computing power infrastructure.HONG KONG, Mar 26, 2026 - (ACN Newswire via SeaPRwire.com) – China International Marine Containers (Group) Co., Ltd. (“CIMC Group” or the “Group”, stock code: 000039.SZ/02039.HK) is pleased to announce the audited annual results for the 12 months ended 31 December 2025 (the “Year”).The Group’s management stated, “In 2025, profound global changes unseen in a century accelerated, and the global economy demonstrated resilience amid volatility. Positioned in an era of both opportunities and challenges, the Group closely adhered to the strategic theme of “accelerating the construction of new growth drivers and focusing on promoting high-quality development”. While stabilising its operating fundamentals, the Group further deepened its forward-looking strategic layout in the energy business and achieved fruitful results. For the year of 2025, the Group recorded revenue of RMB 156.61 billion and net profit of RMB 1.34 billion. Cash flows from operating activities increased significantly by 99.9% to RMB 18.51 billion, with the asset structure continuously optimized and risk resilience further enhanced.”In particular, to sincerely reward investors, CIMC Group proposes to distribute a cash dividend of RMB 0.179 per share (tax inclusive) to all shareholders for 2025, amounting to a total proposed cash dividend of RMB 939 million (tax inclusive). Meanwhile, the Group implemented share buybacks totalling RMB 913 million during 2025, bringing the combined total to RMB 1.852 billion.Segments Results (RMB 100 million)2025 Business indicatorsRevenueAs % of the total revenueGross profitAs % of the gross profitGross profit marginNet profitContainer manufacturing430.0927.46%57.5529.52%13.38%18.82Road transportationvehicles201.7812.88%32.0616.45%15.89%9.27Energy, chemical, and liquid food equipment271.9217.36%40.2420.64%14.80%10.40Offshore engineering179.3811.45%26.6013.65%14.83%10.57Logistics services267.9317.11%16.708.57%6.23%3.64Airport facilities and logistics equipment/fire safety and rescue equipment76.194.86%15.147.76%19.87%2.64Total of major segments1427.2991.12%188.2996.59%13.19%55.34Core Business Performance1. In logistics field:In the container manufacturing business, during the Year, despite negative supply chain factors such as U.S. tariff policies and geopolitical conflicts, global merchandise trade demonstrated strong resilience. Intra-regional trade, Asia-Europe routes and emerging market routes became the main drivers of incremental growth. Meanwhile, factors such as detours around the Red Sea, port congestion, environmental requirements in shipping and increasing complexity of trade routes reduced transportation efficiency, structurally boosting underlying demand and pushing the global container fleet into a new structural phase. As a result, overall demand for new containers in 2025 remained at a relatively high level, exceeding the average of the past decade. During the Year, the production and sales volume of the Group’s container manufacturing business declined YoY, in line with overall industry expectations, but the Group maintained its global No.1 position. Accumulated sales volume of dry cargo containers reached 2,224,900 TEUs (2024: 3,433,600 TEUs), representing a YoY decrease of 35.2%. Accumulated sales volume of reefer containers reached 208,200 TEUs (same period last year: 138,600 TEUs), representing a YoY increase of 50.2%. During the Year, the container manufacturing segment recorded revenue of RMB 43.009 billion, net profit of RMB 1.882 billion, and a slight decline in gross profit margin to 13.38%.In the logistics services business, during the Year, the segment recorded revenue of RMB 26.793 billion, representing a YoY decrease of 14.64%, and net profit of RMB 364 million, representing a YoY decrease of 16.65%, in line with industry trends. CIMC Wetrans actively adjusted its business structure and integrated resources. During the Year, self-sourced cargo volume increased by 6% YoY, while second-hand container trading and warehousing distribution in port logistics reached record highs. The industry logistics business focused on key sectors such as new energy, automotive and engineering projects to consolidate its niche advantages. In 2025, CIMC Wetrans ranked among the top five for three consecutive years in the “Comprehensive List of Freight Forwarding and Logistics Enterprises” published by the China International Logistics and Freight Forwarding Association.In the road transport vehicles business, during the Year, CIMC Vehicles recorded revenue of RMB 20.178 billion, representing a YoY decrease of 3.91%, and net profit of RMB 927 million, representing a YoY decrease of 14.29%. In the domestic market, the “Star-Chained Plan” reshaped the organisational and operational model, with revenue from the China semi-trailer business increasing by 14.65% YoY and gross profit margin increasing by 3.3%YoY. In overseas markets, the Global South markets maintained high-quality growth, with revenue reaching RMB 3.09 billion during the Reporting Period, representing a YoY increase of 17.7%, sales volume increasing by 29.1% YoY, and gross profit margin increasing by 1.3 percentage points YoY.The DTB business achieved steady growth in both sales volume and revenue, with a total of 28,570 units of mounted equipment products delivered, generating total revenue of RMB 3.184 billion, representing a YoY increase of 4.97%, with further improvement in market share of core products. Meanwhile, the Group continued to actively expand R&D and sales of new energy products, comprehensively building the EV-RT ecosystem and advancing the strategic development of pure electric tractors and trailers.In the airport facilities and logistics equipment/fire safety and rescue equipment, benefiting from the release and delivery of high-quality orders, the segment recorded revenue of RMB 7.619 billion during the Year, representing a YoY increase of 5.92%, and net profit of RMB 264 million. Airport equipment successfully delivered smart boarding bridges projects for Xi’an Xianyang International Airport, Antalya Airport in Türkiye and Lanzhou Airport, and secured major projects including Phase II of Nanning Airport and corridor projects at Hangzhou Airport T2 and T4 with its independently-developed innovative prefabricated fixed bridge solutions. Logistics equipment delivered automated three-dimensional warehouse systems for supporting the petrochemical and refining integration project in China. The fire safety and rescue equipment business advanced the overseas expansion of domestically manufactured products while focusing on frontier areas such as smart fire safety and unmanned fire trucks.2. In the Energy FieldIn the energy, chemical, and liquid food equipment business, the segment recorded revenue of RMB 27.192 billion, representing a YoY increase of 6.31%, and net profit increased significantly by 42.15% to RMB 1.040 billion. Among which, CIMC Enric recorded revenue of RMB 26.326 billion, representing a y YoY increase of 6.3%.Specifically, the clean energy segment advanced both offshore and onshore businesses, maintaining leading market share in key equipment such as high-pressure and cryogenic equipment, while capturing growth opportunities in natural gas applications in water and land transportation and power generation, and actively expanding into emerging markets for special industrial gas equipment in high-tech industries. In 2025, the segment secured new orders of RMB 22.229 billion, a record high. Among these, orders on hand for offshore clean energy-related business exceeded RMB 19 billion as of the end of 2025, with shipbuilding schedules extending to 2028. During the Year, the second coke oven gas comprehensive utilisation project — Linggang Phase I project — was successfully put into operation, and China’s first domestic mass-production bio-methanol (green methanol) project of CIMC Enric was completed and commenced operation. The chemical and environmental segment maintained its leading market share, while the medical equipment components and after-sales service businesses achieved steady growth. As of the end of 2025, orders on hand increased by 36.27% YoY to RMB 1.276 billion, providing strong support for future development. The liquid food segment maintained stable profitability, with gross profit margin increasing to 21.7% YoY.In the offshore engineering business, the Group’s core operating entity, CIMC Raffles, successfully achieved a strategic transformation from “manufacturing-led” to integrated “design + construction + integration” services, maintaining a leading position in the domestic market and emerging as an important new force in the international offshore engineering market. During the Reporting Period, the segment recorded revenue of RMB 17.938 billion, representing a YoY increase of 8.35%, and net profit of RMB 1.057 billion, becoming the Group’s second-largest profit contributor. Benefiting from the recovery of the global offshore engineering market, demand for high-end oil and gas equipment represented by FPSO/FLNG remained strong, while the industry accelerated its transition toward green and intelligent development, driving steady growth in new energy equipment orders. During the year, the Group secured new contract orders of US$1.20 billion, including 12+8 container feeder vessels, 2 offshore engineering special vessels and other module orders. As of the end of 2025, the accumulated value of orders on hand reached US$5.09 billion, with orders for oil & gas and special vessel accounting for approximately 70% and 30%, respectively. The Longkou base has scheduled production through to 2030.In the offshore engineering asset operation and management business, the Group continued to leverage its existing project experience and business capabilities, enhancing asset utilisation through its strong offshore platform operation and management capabilities. During the Reporting Period, the sixth-generation semi-submersible drilling platform “Deepsea Yantai” completed lease renewal, the ultra-deepwater semi-submersible drilling platform “Blue Whale No.1” signed a new lease with an international client, and the semi-submersible lifting/life platform “Blue Gretha (formerly Huadian CIMC 01)” also secured a new lease with an international client. Other platforms actively participated in market tenders to explore opportunities for asset disposal and leasing. During the Reporting Period, the average daily lease rate of semi-submersible and jack-up drilling platforms both recorded year-on-year increases.Future Development and ProspectsThe Group’s management stated, “The year 2026 marks the beginning of the ‘15th Five-Year Plan’. Starting from a newly upgraded brand identity, the Group will closely focus on ‘consolidating foundations, driving innovation, improving quality and efficiency’, and adopt a more proactive strategic approach to foster new opportunities and open new horizons amid complex changes, striving to build a ‘“becoming a high quality and trustworthy world-class multimodal transport enterprise.”About China International Marine Containers (Group) Co., Ltd.The CIMC Group is a world-leading equipment and solution provider in the logistics and energy industries, with its industry clusters mainly covering the logistics and energy fields, continuously strengthening its leading market position. In the logistics field, the Group continues to adhere to container manufacturing as its core business, based on which it has incubated the road transportation vehicles business and the airport facilities and logistics equipment / fire safety and rescue equipment business, supplemented by the logistics services business and recycled load business, providing products and services in the professional logistics field. In the energy field, the Group is principally engaged in the energy, chemical and liquid food equipment business and the offshore engineering business. Meanwhile, the Group continues to develop emerging industries and possesses financial and asset management businesses that serve the Group itself. As a diversified multinational industrial group serving the global market, CIMC has over 300 member enterprises across Asia, North America, Europe, and Australia, with a total of four listed companies, and customers and sales networks covering more than 100 countries and regions worldwide. In 2025, the Group recorded revenue of RMB 156.6 billion, ranking 154th on the 2025 Fortune 500 China list. The Group has maintained the world’s No.1 position for many consecutive years in core products such as standard dry containers, reefer containers, tank containers and semi-trailers. For more information, please visit http://www.cimc.com/. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Financial Highlights (Audited)(HKD Thousand)Year ended31 December20252024Revenue170,011271,372Gross Profit53,382104,720Profit Attributable to Owners of the Company13,68833,440Basic Earnings per Share (HK cents)0.972.37HONG KONG, Mar 26, 2026 - (ACN Newswire via SeaPRwire.com) - Dynasty Fine Wines Group Limited (“Dynasty” or “the Group”) (Stock Code: 00828), a premier grape winemaker in China, today announced its audited annual results for the year ended 31 December 2025 (“the Year”).In 2025, due to the impact of macroeconomy as well as weak demand in wine consumer market in the PRC, the Group’s sales of medium to high-end products significantly declined, resulting in a 37% year-on-year decrease in revenue to HK$170.0 million. In addition, due to the decline in sales revenue and gross margin, as well as an increase in loss allowances for trade receivables owing to extended repayment from certain distributors, the profit attributable to owners of the Company decreased by 59% year-on-year to approximately HK$13.7 million, although such decrease in profit was already partly offset by a net gain on compensatory surrender recognised during the year. Earnings per share of the Company was HK0.97 cents per Share.With strengthened marketing effort for dry white in coastal region and the launch of new white wine and sparkling wine products, sales of white wine products served as the Group’s primary revenue contributor. Sales of red and white wines products accounted for approximately 39% and 54% of the revenue respectively for the year (2024: approximately 41% and 56% respectively). The gross margin of red wine products and white wine products in 2025 were 25% and 35% respectively (2024: 36% and 41% respectively). The overall gross profit margin decreased to 31% in 2025 (2024: 39%), mainly due to change in product mix with more products with lower prices and margin in response to market dynamics and needs during the year.The Group has been actively pursuing innovation, embracing the “5+4+N” product strategy, with “N” standing for developing various customised products and continuously creating new products to meet the diverse needs of different Chinese consumer groups. During the year, the Group launched a new gift set product, i.e. Dynasty Chinese Zodiac Commemorative Dry Red Wine for the Yi Si Year of Snake, integrating with the Chinese zodiac culture and the leading rise of Chinese-style fashionable products, by presenting the zodiac culture in a youthful visual language to attract potential consumers. In addition, based on its existing high-quality products, the Group continues to introduce new products and promote product upgrades. The Group participated in the 112th China Food & Drinks Fair in March 2025, introducing new products such as Tianyang Tea-flavoured wine series, Dynasty Baifu VSOP brandy, etc., to further improve its product matrix and provide consumers with diverse consumption choices. Breaking through from the constraints of traditional wine, this tea-flavoured wine series, with its core concept of “tea and wine fusion,” has captured market attention with its unique craftsmanship. During the China Food & Drinks Fair, the Group also held wine-tasting events, where the new wines from Dynasty Ningxia Winery won industry praise for their unique flavor and exquisite craftsmanship. In the second half of the year, the Group also introduced new products “Hi” tea-flavoured wine series in response to the market need, which are very suitable for ready-to-drink scenarios among young consumers.In addition to enriching the product matrix, the Group has been closely cooperating with distributors, pressing ahead with its marketing campaign, accelerating the innovation of consumption scenarios, and enhancing and strengthening the wine cultural experience. The Group held its national tour tasting and business events, new products launch ceremonies at various exhibitions and wine fairs, as well as promotion activities for the 20th anniversary of listing in Hong Kong, during which the Group actively promoted its latest product mix that covered all product lines.During the year, two joint venture companies approved by the Group were established in February 2025, for the manufacturing and sales of yellow wine and Chenpi wine and trading of sauce-flavour baijiu products nationwide in the PRC respectively. For the yellow wine project, installation and testing of production equipment of a manufacturing plant with a tank capacity of 3,000 tonnes of yellow wine and special yellow wine – Chenpi wine in Jiangsu is expected to be completed in the second half of 2026. Upon completion of the project, the Group will be able to produce special yellow wine – Dongtai Chenpi Wine which allows the Group to effectively expand product categories, seize development opportunities in the Chinese yellow wine industry. The project expansion aims to effectively implement Dynasty’s strategic plan, further improving the industrial layout, expanding category tracks, tapping into industry potential, creating new performance growth points, and realising Dynasty Group’s transformation into a full category, full industry-chain enterprise. For the sauce-flavour baijiu segment, Dynasty sauce-flavour baijiu products, namely ‘Han’, ‘Tang’, ‘Song’ and ‘Ming’ have been newly launched in the core-market in Tianjin and Shanghai and will be further strategically promoted to other regions in 2026. The sauce-flavour baijiu products satisfy the needs of customer groups with different spending habits and contributing to the Group’s business. In the future, the continuous development and expansion of the sauce-flavour baijiu industry and the improvement of the level of customer groups will inevitably and effectively drive the increase in the sales scale of Dynasty wine and related products, thereby enhancing our industry influence and brand awareness.Regarding online sales, the e-commerce team of the Group comprehensively operates online stores itself on the traditional e-commerce platforms, such as JD.com, Tmall and Pinduoduo for product sales, as well as comprehensive innovation on its brand, product categories, and business systems, procedures and models via interest-based e-commerce platforms, including Rednote, Kuai and TikTok. The Group continues investing resources in a timely manner for improvement of the online sales channels and optimisation of online stores interface so as to capture the change of customer consumption behaviour in the PRC. The Group jointly develops exclusive products with leading e-commerce platforms, and promote AI livestreaming models in various channels to increase brand exposure and livestreaming sales, adopts big data analysis to accurately understand consumer demand, and injects strong momentum into the continued expansion of market scale. To establish an online brand matrix, the Group selected and authorised new online distributors during the year. The Group believes that the online platforms not only serve as business-to-customer trading platforms between the Group and the consumers, but also additional marketing and promotion channels for the brand, which can enhance the overall business potential of the Group.During the year, the Group had boasted brilliant results in major wine appraisal competitions. Among the numerous awards, “Dynasty Jin. Y Brandy XO barrel-aged 12 years” has won the Silver Award, at the 2025 International Wine & Spirit Competition (“IWSC”). The competition is considered the international standard for wine and spirits quality. Dynasty Baifu VSOP Brandy, Golden Dynasty Marselan Dry Red Wine, as well as Tianyang Tea Wine series are also awarded at the “2024 Qingzhuo Awards” in respective categories by China Alcoholic Beverages Association. “Dynasty Mengyuan White wine” has also won the Grand Gold Medal at the France International Wine Awards (“FIWA”) China region, Spring 2025 for its excellent quality. In addition, “Dynasty Inherit series – Dry Red Wine” has garnered the Gold Award at the same competition. These wines stood out from other entries for their elegant aroma, smooth body and round taste, and won the awards at the competitions, showing the charm and strengths of Dynasty wines to the country and the world. Dynasty has won the Silver Medal in the Sparkling Wine/China category, the Silver Medal in the Dry Wine/China category, and the Bronze Medal in the Medium/China category for its Dynasty Tianyang Winery Jasmine Sparkling Wine, Dynasty Inherit Series – Dry Red Wine, and Dynasty Inherit Series – Semi Dry White Wine, respectively, at the 2025 Cathay Global Wine & Spirits Awards Asia (“GWSAA”) (formerly known as the Cathay Hong Kong International Wine & Spirit Competition (“HKIWSC”)). This marks the 15th consecutive year that Dynasty products have won awards at the event, demonstrating industry-wide recognition of Dynasty’s exceptional winemaking skill and quality. In addition, “Dynasty Pinyue VSOP brandy” also won the Gold Medal in the brandy category of 2025 China Fine Wine Challenge.Mr. Wan Shoupeng, Chairman of Dynasty, concluded, “Looking ahead to 2026, the Group will continue to focus on market and consumer demand, reinvent consumption scenarios and promote product quality. At the same time, the Group will continue to innovate marketing strategies to stimulate brand vitality, further expand the market share of Dynasty’s products, strengthen Dynasty’s brand image as a representative of domestic wines, and set a benchmark for the Chinese wine industry, with the aim of bringing Dynasty’s superior wines to more consumers in the PRC. The Group will continue to uphold quality, seize the development trend of low-alcohol and younger consumer markets, and proactively develop new marketing prospects through innovation in products categories and consumption scenarios.”About Dynasty Fine Wines Group LimitedDynasty Fine Wines Group Limited was listed on the Main Board of The Stock Exchange of Hong Kong Limited with the stock code 00828 on 26 January 2005. Founded in 1980, Dynasty is the premier grape winemaker in China. It is principally engaged in the production and sale of grape wine products under its reputable “Dynasty” brand. Dynasty is the first Sino-foreign joint venture wine company in China with Tianjin Food Group Limited and the French grape wine giant, Remy Cointreau, as its current major shareholders. The Group produces and sells more than 100 grape wine product series, and introduces imported wine products, providing high-quality and value-for-money grape wines to the full range of consumer groups in China.For media enquiries:Strategic Financial Relations (China) LimitedMs. Anita Cheung Tel: 2864 4827Ms. Gianna Ye Tel: 2864 4837Ms. Hazel Ye Tel: 2864 4893Ms. Chloe Lyu Tel: 2864 4835Email: sprg-dynasty@sprg.com.hk Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

财务摘要 (经审核)（港币千元）截至十二月三十一日止年度 2025年2024年收入170,011271,372毛利53,382104,720本公司所有者应占溢利13,68833,440每股基本盈利 (港仙)0.972.37香港, 2026年3月26日 - (亚太商讯 via SeaPRwire.com) - 中国优质葡萄酒生产商王朝酒业集团有限公司(「王朝」或「集团」)(股份代号：00828)今日公布截至2025年12月31日止（「年内」）经审核之全年业绩。2025年，受宏观经济和中国葡萄酒消费市场需求疲弱的情况影响，集团中高档产品销售下滑，收入较去年同比减少37%至1.70亿港元。另外由于销售收入及毛利率下降，以及部分经销商延迟还款导致应收账款亏损拨备增加，本公司所有者应占溢利较去年同比减少59%至13.7百万港元，尽管溢利减少部分已被年内确认的补偿交出净收益所抵消。集团每股基本盈利为每股0.97港仙。随着集团在沿海地区加大对干白葡萄酒市场的推广力度，并推出新款白葡萄酒及起泡酒产品，白葡萄酒产品的销售已成为集团的主要收入来源。红葡萄酒及白葡萄酒产品的销售分别占集团于年内收入的约39%及54%（2024年：分别为约41%及56%）。于2025年，红葡萄酒产品及白葡萄酒产品的毛利率分别为25%及35%（2024年：分别为36%及41%）。整体毛利率减少至31%（2024年：39%），主要由于年内因应市场动态及需求调整产品组合并降低销售价格及利润率。集团积极求新，聚焦「5+4+N产品战略」，其中「N」代表集团推出N项需求定制，不断开拓创新产品，以满足中国不同类型消费群体的多元化需求。年内，集团推出礼盒新品－王朝乙巳蛇年生肖纪念干红葡萄酒，与中国生肖文化相融合，引领「国潮风」，以年轻化的视觉语言呈现生肖文化，吸引潜在消费者。此外，基于其现有的优质产品，集团继续推出新产品并推进产品升级。集团于2025年3月在第112 届全国糖酒商品交易会上推出天阳茶酒系列、王朝百馥VSOP白兰地等新品，以进一步完善其产品矩阵，为消费者提供多元的消费选择。该系列茶香葡萄酒突破传统葡萄酒的局限，以「茶酒融合」为核心理念，凭借独特的酿造工艺迅速获得市场目光。在全国糖酒商品交易会期间，集团亦举办品酒会，而王朝宁夏酒庄的新品凭借独特的风味和精湛的酿造工艺，赢得业界的好评。下半年，集团亦因应市场需求，推出全新产品「嗨」茶风味酒系列，非常适合年轻消费者的即饮场景。除了丰富产品矩阵外，集团与经销商紧密合作，积极推进市场推广活动，加速创新消费场景，提升及强化葡萄酒文化体验。集团于各类展览及葡萄酒博览会举行期间，举办了全国巡回品鉴会及招商活动、新品发布会以及香港上市20周年推广活动，期间集团大力推广其全系列的最新产品组合。年内，集团批准设立的两间合资公司于2025年2月成立，分别从事黄酒及陈皮酒生产及销售，以及于全国范围内买卖酱香型白酒产品。对于黄酒项目，江苏的一座储罐容量为3,000 吨黄酒及特种黄酒－陈皮酒的生产设备及安装及测试预期将于2026年下半年完成建设。于项目完成后，集团将能够生产特种黄酒－东台陈皮酒，让集团可有效扩展产品品类，把握中国黄酒行业的发展机遇，进一步优化集团产业布局，拓展品类版图，实现王朝向全品类、全产业链企业的转型。对于酱香型白酒领域，王朝酱香型白酒产品，即「汉」、「唐」、「宋」、「明」，已于天津及上海核心市场新推出，并将于2026年进一步战略推广至其他地区。酱香型白酒产品满足不同消费习惯的客户群体的需求，并为集团业务作出贡献。未来，酱香型白酒产业的持续发展及扩张及客户群体水平的提升，必将有效推动王朝葡萄酒及相关产品销售规模的增长，从而提升行业影响力及品牌知名度。电商销售方面，集团的电商团队于传统电商平台全面运营在线商店销售产品，例如京东商城、天猫商城及拼多多，以及通过兴趣电商平台（包括小红书app、快手app 及抖音app）全面创新品牌、品类、业务体系、流程和模式。集团继续为改善网上销售渠道及时投入资源，优化在线商店界面，以把握中国客户消费行为的变化，与头部电商平台共同开发专属产品，并通过多种渠道推广人工智能直播模型以提升品牌曝光度及直播销售额，采用大数据分析以精准洞察消费者需求，为市场规模持续扩大注入强劲动力。为建立在线品牌矩阵，集团于年内甄选及开放新店在线经销商授权。集团相信线上平台不仅是集团与消费者之间的企业对客户交易平台，亦是品牌新增的市场推广及宣传渠道，从而提升集团的整体业务潜力。年内，集团在大型葡萄酒品鉴大赛中屡获殊荣。在多个奖项中，「王朝锦邑桶藏12年XO白兰地」荣获2025年国际葡萄酒与烈酒大赛（「IWSC」）中的银奖。该比赛被视为葡萄酒和烈酒质量的国际评价标准。王朝百馥VSOP白兰地、金王朝马瑟兰干红葡萄酒以及天阳茶酒系列亦于中国酒业协会举办的「二零二四年青酌奖」各类别评选中获奖。「王朝梦园白葡萄酒」亦以其卓越的酒质荣获2025年春季FIWA法国国际葡萄酒大奖赛中国区金奖。此外，「王朝传承系列－干红葡萄酒」于同一比赛中荣获金奖。该等葡萄酒因其酒香优雅、酒体顺滑和口感圆润从众多参赛作品中脱颖而出，并在比赛中获得奖项，向国家及世界展示了王朝葡萄酒的魅力和实力。王朝旗下产品「王朝天阳酒庄茉莉葡萄起泡酒」、「王朝传承干红葡萄酒」以及「王朝传承半干白葡萄酒」分别于2025年度国泰环球葡萄酒及烈酒大奖亚洲（「GWSAA」）（前称国泰航空香港国际美酒品评大奖（「HKIWSC」））荣获中国产区品评组别下气泡酒、干型酒银奖殊荣，以及中国产区品评组别下半干型酒铜奖殊荣。这是王朝产品连续15年于该奖项中获得佳绩，标志着王朝在葡萄酒酿造技艺与卓越质量方面再次获得业界的高度认可。此外，「王朝品悦VSOP白兰地」在2025年中国优质葡萄酒挑战赛中荣获白兰地类别金奖。王朝主席万守朋先生总结︰「展望2026年，本集团将继续以市场及消费者需求为导向，重塑消费情景，提升产品质量。同时，本集团将继续创新市场营销策略，激发品牌活力，进一步扩大王朝产品的市场占有率，加强王朝品牌作为国产葡萄酒代表的形象，并为中国葡萄酒行业树立标杆，将王朝美酒风尚带给更多的中国消费者。本集团将继续秉持质量至上，把握低酒度饮品及年轻消费者市场的发展趋势，并通过产品品类及消费场景的创新，积极开拓新的市场前景。」关于王朝酒业集团有限公司王朝酒业集团有限公司于2005年1月26日在香港联合交易所有限公司主板上市，股份代号00828。成立于1980年，王朝为中国优质葡萄酒生产商，主要生产及销售「王朝」商标的葡萄酒产品，是中国第一家中外合资的酿酒企业，主要股东包括天津食品集团有限公司及法国葡萄酒巨头人头马集团。集团产销葡萄酒产品系列超过100种，及引入进口葡萄酒产品，为国内各消费层提供高质素及物超所值的葡萄酒。新闻垂询：纵横财经公关顾问(中国)有限公司张丽云小姐 电话：2864 4827叶甘霖小姐 电话：2864 4837叶婉铃小姐 电话：2864 4893吕昕纯小姐 电话：2864 4835电邮：sprg-dynasty@sprg.com.hk Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Mar 26, 2026 - (ACN Newswire via SeaPRwire.com) - The Census and Statistics Department today released the latest external merchandise trade statistics. In February 2026, the total value of merchandise exports increased by 24.7% year-on-year to $408.8 billion. For the first two months of 2026, the total value of exports of goods amounted to $928.3 billion, marking an increase of 29.6% from the same period of last year.Hong Kong Trade Development Council’s Director of Research Bruce Pang said, over the past few months, Hong Kong’s external trade has continued to exhibit clear growth momentum. Although global geopolitical conditions remain tense, underlying demand from the Chinese Mainland and major overseas markets has remained resilient. We maintain a positive outlook, yet remain cautious in regard to Hong Kong’s trade performance.”HKTDC Media Room: https://mediaroom.hktdc.com/enMedia enquiriesPlease contact the HKTDC’s Communications & Public Affairs Department:Jane CheungTel: (852) 2584 4137Email: jane.mh.cheung@hktdc.org Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

NEW YORK, N.Y., Mar 26, 2026 - (ACN Newswire via SeaPRwire.com) - OpenClawd AI today released a security-focused platform update that adds automated skill vetting, verified installer sourcing, and runtime sandboxing to its managed OpenClaw hosting service. The update responds to two converging threats targeting users of the open-source AI agent formerly known as Clawdbot and Moltbot: a large-scale malware campaign inside the official OpenClaw skill marketplace, and a parallel wave of counterfeit installation packages being promoted through search engine results.The numbers are bad enough on their own. Together, they describe a supply chain that is actively hostile to casual users.One in Eight OpenClaw Skills Is Confirmed MaliciousIndependent security researchers recently completed an audit of the ClawHub skill marketplace — the primary distribution channel for third-party OpenClaw plugins. Out of 2,857 published skills, 341 were confirmed as malicious. That is approximately 12% of the entire marketplace.The findings include:Keyloggers and credential stealers deployed through skills that appear to offer legitimate productivity featuresSilent data exfiltration — one widely-downloaded skill was found to instruct the OpenClaw agent to execute curl commands that sent user data to an external server without any notification or consent promptPrompt injection payloads embedded in skill descriptions, designed to override the agent’s safety guidelines and force execution of unauthorized commandsPlaintext credential exposure — a separate audit found that over 280 additional skills were leaking API keys, tokens, and passwords in their source codeA major cybersecurity firm tested a specific ClawHub skill and published the results: nine security findings, including two critical and five high-severity issues. The skill functioned as what the researchers called “functionally malware.” The most widely-downloaded malicious skill on ClawHub was a cryptocurrency stealer.Fake OpenClaw Installers Are Being Promoted by Search EnginesThe marketplace problem is only half the story. A cybersecurity research team discovered that threat actors have published counterfeit OpenClaw installation packages on open-source code repositories. These fake installers mimic the legitimate OpenClaw setup process but instead deliver a malware packer that disables firewall protections and routes network traffic through compromised systems.The attack chain is straightforward: a user searches for “install OpenClaw” or “Clawdbot download.” An AI-powered search engine returns a result linking to the malicious repository. The user follows the instructions. The malware deploys silently.The researcher who discovered the campaign noted that the person who first reported the threat was a technical professional. “If a fellow IT pro is susceptible to this threat,” he said, “then anyone could be.”“There are now two ways to get compromised before you even run your first OpenClaw command,” said Danny Wilson, spokesperson for OpenClawd. “You can install a fake version of the software, or you can install the real version and then add a skill that steals your data. We built this update so that neither path exists on our platform.”What OpenClawd Ships TodayThis update targets both the supply chain and the runtime:Verified installer sourcing — all OpenClawd instances are provisioned from cryptographically signed OpenClaw releases, pulled directly from the official repository. No third-party install paths. No search engine intermediaries.Skill vetting pipeline — third-party skills go through automated static analysis and behavioral testing before activation. Skills flagged for network exfiltration, prompt injection patterns, or credential exposure are blocked by default.Runtime sandboxing — each skill executes in an isolated environment with explicit permission boundaries. A skill that requests network access to an unexpected endpoint triggers a review before execution.Credential isolation — API keys and tokens are stored in encrypted vaults and never exposed in plaintext to skill code or agent logsAutomatic CVE patching — hosted instances track the latest stable OpenClaw release (currently v2026.3.x), with all known vulnerabilities patched before deploymentOpenClawd does not operate its own skill marketplace. Skills available on hosted instances are drawn from the official ClawHub repository after passing the vetting pipeline described above.OpenClawd is not affiliated with the OpenClaw open-source foundation, OpenAI, Peter Steinberger, or any third-party security research firm cited in this release. It is an independent platform built on the open-source Clawdbot codebase. The open-source project remains free at github.com/openclaw/openclaw.Pricing starts with a free tier. Paid plans include dedicated compute, priority security patching, and uptime monitoring. Deploy a secure OpenClaw instance at https://openclawd.ai.Contact:Email: support@openclawd.ai Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Development Highlights- During the Year, the Group had 4 innovative products approved for marketing by the NMPA, namely, Saitanxin(R) (Culmerciclib Capsules), Hernexeos(R) (Zongertinib Tablets), Putanning(R) (Meloxicam Injection (II)) and Anqixin(R) (Recombinant Human Coagulation Factor VIIa N01 for Injection).- In 2025, the Group’s sales of innovative products reached RMB 15.22 billion, representing a year-on-year increase of 26.2%. In addition, the Group has established multiple R&D centers in Shanghai, Nanjing, Beijing, Guangzhou, and other cities, and has successfully built diversified innovative technology platforms covering small molecules, protein degraders, siRNA, monoclonal/bispecific antibodies, antibody-drug conjugates (ADC), inhalable formulations, transdermal patches and other fields.- As at 31 December 2025, the Group had a total of 39 innovative oncology drug candidates, 10 innovative liver/cardiometabolic drug candidates, 14 innovative respiratory/autoimmune drug candidates, and 6 innovative surgery/analgesia drug candidates in the process of clinical trial application or above. Of these, 1 innovative oncology drug candidate and 2 innovative surgery/analgesia drug candidates are in the marketing application stage; and 13 innovative oncology drug candidates, 1 innovative liver/cardiometabolic drug candidate, 5 innovative respiratory/autoimmune drug candidates, and 1 innovative surgery/analgesia drug candidate are in Phase III clinical trials. Also, 9 innovative oncology drug candidates, 6 liver/cardiometabolic drug candidates, 5 innovative respiratory/autoimmune drug candidates, and 2 innovative surgery/analgesia drug candidates are in Phase II clinical trials. In addition, the Group had a total of 16 innovative oncology drug candidates, 3 innovative liver/cardiometabolic drug candidates, 4 innovative respiratory/autoimmune drug candidates, and 1 innovative surgery/analgesia drug candidate in Phase I clinical trials.- Focus V(R) (Anlotinib Hydrochloride Capsules) is a novel small molecule multi-target tyrosine kinase inhibitor that has been approved for 10 indications. It has several new indications currently in Phase III clinical studies, including first-line non-squamous non-small cell lung cancer and first-line pancreatic cancer, with plans to gradually submit marketing applications within the next two years.- From 2023 to 2025, the Group obtained marketing approval for 7 national category 1 innovative oncology drugs, namely, Saitanxin(R) (Culmerciclib capsule), Hernexeos(R) (Zongertinib table), Yilishu(R) (Efbemalenograstim alfa Injection), Andewei(R) (Benmelstobart Injection), Anboni(R) (Unecritinib Fumarate Capsules), Anluoqing(R) (Envonalkib Citrate Capsules), and Anfangning(R) (Garsorasib Tablets). It also obtained marketing approval for 4 oncology biosimilars, including Anbeisi(R) (Bevacizumab Injection), Delituo(R) (Rituximab Injection), Saituo(R) (Trastuzumab for Injection), and Paletan(R) (Pertuzumab Injection). The sales volume of these products accelerated rapidly in 2025, and they have become important contributors to the Group’s revenue growth.- Tianqing Ganmei(R) (Magnesium Isoglycyrrhizinate Injection) is the fourth-generation of glycyrrhizic acid preparation that has been approved for 3 indications. During the Year, the Group made efforts to strengthen academic promotion, expanding doctor coverage and gaining recognition from experts through academic conferences at all levels, while vigorously exploring new patients to expand into new markets, and actively promoting retrospective research to provide more academic evidence for its clinical use.- TQC3721 (PDE3/4 inhibitor) is a dual PDE3/4 inhibitor currently undergoing Phase III clinical trials in China for the treatment of moderate to severe chronic obstructive pulmonary disease (COPD). The Group is developing a variety of dosage forms of TQC3721: a suspension for inhalation is in Phase III clinical trials, and an inhaled dry powder formulation is in Phase II clinical trials. The different dosage forms are expected to further enhance patient compliance.- Zepolas(R)/Debaian(R) (Flurbiprofen Cataplasms) is the first domestically produced cataplasms approved for marketing in China, ranking first in the market share of topical analgesia for many years. The Group focuses on the development of highpotential regions, further expanding its market coverage and gradually increasing its production capacity to meet the booming market demand, driving the sustained rapid sales growth of Zepolas/Debaian. The second-generation flurbiprofen patch developed by the Group is expected to be approved for marketing within one year. With formulation enhancements, the second-generation product can significantly improve the transdermal absorption of the drug and enhance the adhesiveness of the plaster, thereby improving patient compliance.HONG KONG, Mar 26, 2026 - (ACN Newswire via SeaPRwire.com) – Sino Biopharmaceutical Limited (“Sino Biopharmaceutical” or the “Company”, together with its subsidiaries, the “Group”) (HKEX stock code:1177), a leading innovation-driven pharmaceutical conglomerate in the PRC, has announced its audited financial results for the year ended 31 December 2025 (the “Year”).During the Year, the Group's revenue increased by approximately 10.3% to approximately RMB31.83 billion. Profit attributable to owners of the parent from continuing operations (as reported) was approximately RMB2.34 billion, a year-on-year increase of approximately 22.0%. Basic earnings per share attributable to owners of the parent from the continuing operations were approximately RMB13.02 cents, an increase of approximately 24.0% over last year. Underlying profit attributable to owners of the parent totaled approximately RMB4.54 billion, a year-on-year increase of approximately 31.4%. The Group’s liquidity remained strong, with cash and bank balances classified as current assets of approximately RMB12.18 billion, bank deposits classified as non-current assets of approximately RMB10.25 billion, wealth management products of approximately RMB10.56 billion in total, and total fund reserves of approximately RMB32.99 billion for the Year.The Board of Directors has recommended a final dividend payment of HK5 cents per share (2024: HK4 cents). Together with an interim dividend of HK5 cents already paid, the total dividend for the year amounts to HK10 cents (2024: HK7 cents).Sales: Innovation-driven growth fuels sustained sales momentumDuring the Year, the Group consistently increased investments to enhance R&D quality and efficiency, which led to a marked strengthening of R&D capabilities, driving sustained sales revenue growth and delivering substantial results. Sales of innovative products increased by 26.2% year-on-year to approximately RMB15.22 billion, accounting for approximately 47.8% of the Group’s revenue. If the sales is categorized by therapy field, sales of oncology drugs increased by 22.8% year-on-year to approximately RMB13.18 billion, accounting for approximately 41.4% of the Group's revenue. Sales of surgical/analgesic medications increased by 12.8% year-on-year to approximately RMB5.03 billion, accounting for approximately 15.8% of the Group's revenue.In the field of oncology, the Group has a comprehensive layout in non-small cell lung cancer (NSCLC), covering the full-line treatment of multiple subtypes. Focus V(R) (Anlotinib Hydrochloride Capsules) has been approved for 10 indications, and several new indications are currently in the marketing application or Phase III clinical trial stage. Its combination therapy has demonstrated superior efficacy in the treatment of lung cancer. From 2023 to 2025, the Group obtained approval for and launched a total of 7 national category 1 innovative oncology drugs and 4 oncology biosimilars. The sales volume of these products accelerated rapidly in 2025, and they have become important contributors to the Group’s revenue growth.In the field of surgery/analgesia, Zepolas(R)/Debaian(R) (Flurbiprofen Cataplasms) have ranked first in market share of topical analgesia for many years. The second-generation flurbiprofen patch is anticipated to receive marketing approval within the year and is expected to strengthen its market leadership through this dosage form upgrade. Meanwhile, Putanning(R) (Meloxicam Injection (II)), China’s first once-daily long-acting analgesic NSAIDs injection, was approved for marketing by the NMPA and the FDA in May 2025 and has been included in the NRDL in 2025. It is expected to become another blockbuster product for the Group in pain management area.R&D: Technology-driven advancements significantly enhance R&D quality and efficiency R&D innovation has always been the key driving force of the Group. The Group has established multiple R&D centers in places including Shanghai, Nanjing, Beijing, and Guangzhou, and has successfully built diversified innovative technology platforms covering such fields as small molecules, protein degraders, siRNA, monoclonal/bispecific antibodies, antibody-drug conjugates (ADC), inhalation formulations, and transdermal patches. For the year ended 31 December 2025, the Group’s total R&D investment amounted to approximately RMB 6.32 billion, accounting for approximately 19.8% of Group revenue.The Group also attaches tremendous importance to the protection of intellectual property rights and actively files patent applications to enhance its core competitiveness. During the Year, the Group filed 1,167 new patent applications and received 273 patent grants. As at the end of the Year, the Group had accumulated 5,724 valid patent applications and obtained 2,120 valid patent grants.Prospects: Focusing on innovation and firmly promoting internationalization strategyLooking ahead, the Group will continue to focus on innovation and remain deeply committed to four core therapeutic areas – oncology, liver / cardiometabolic diseases, respiratory/autoimmune diseases, and surgery/analgesia. It will leverage AI to deeply empower the entire R&D process and continuously strengthen its R&D and innovation capabilities to drive steady business growth. Over the next three years (2026-2028), the Group’s innovation pipeline is expected to experience another wave of explosive growth, with nearly 20 national category 1 innovative drugs expected to be approved for marketing, including multiple blockbuster products with first-in-class (FIC) and best-in-class (BIC) potential. It is expected that by the end of 2028, the total number of innovative products launched by the Group will be around 40, positioning them as the core driver of business growth.At the same time, the Group will firmly advance its internationalization strategy. In February 2026, the Group announced that it had granted Sanofi an exclusive worldwide license to develop, manufacture, and commercialize Rovadicitinib, with the right to receive payments of up to US$1.53 billion, plus tiered royalties of up to double digits based on annual net sales of Rovadicitinib. Going forward, out-licensing will become another important source of revenue for the Group, continuously injecting strong, new momentum into its performance growth and formally launching a second growth curve supported by revenue from internationalization. In addition, the Group remains committed to adhering to the "win-win cooperation" philosophy and is dedicated to building an open and diverse innovation ecosystem. Through in-depth cooperation with the world's leading pharmaceutical companies, biotechnology firms and scientific research institutions, the Group is accelerating the aggregation of high-quality global resources, promoting the co-creation and sharing of innovative outcomes, and continuously strengthening its market leadership. Through the integration of high-quality resources such as LaNova Medicines and Hygieia, the Group has significantly strengthened its R&D capabilities in cutting-edge fields, including tumor immunology and siRNA.Looking ahead, the Group will continue to drive innovation through its dual engines of internal R&D and strategic cooperation, accelerate its development through internationalization, and make steady progress towards its strategic goal of becoming a world-class innovative pharmaceutical company.For detailed information on the Group’s results for the Year, please refer to the official announcements uploaded by the Group to the Hong Kong Stock Exchange website and its official website.About Sino Biopharmaceutical Limited (HKEX:1177)Sino Biopharmaceutical Limited, together with its subsidiaries, is a leading, innovative R&D-driven pharmaceutical group in China. Its business covers the entire industrial chain, including R&D platforms, intelligent manufacturing, and a robust sales system. Its products encompass a wide range of biologics and chemical drugs, with a strong presence in four core therapeutic areas: oncology, liver/cardiometabolic diseases, respiratory/autoimmune diseases, and surgery/analgesia. The company was listed on the Hong Kong Stock Exchange in 2000, was included as a constituent of the MSCI China Index in 2013, became a constituent of the Hang Seng Index in 2018, and was added to the Hang Seng Stock Connect Biotech 50 Index and the Hang Seng China (Hong Kong-listed) 25 Index in 2020. The company has been named among the "Top 50 Global Pharmaceutical Companies" by the authoritative U.S. magazine Pharm Exec for seven consecutive years, and has been recognized as one of the "Top 50 Best Companies in Asia" by Forbes Asia for three consecutive years.For more information, please visit: www.sbpgroup.com Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com